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ABSTRACT
Transforming growth factor (TGF-ß) potently arrests cell cycle progression by
interfering with the G1/S-phase transition. TGF-ß transduces its signal via the
receptor-Smad pathway and inhibits the activities of cyclin-dependent kinases (Cdk) -
4, -6, and –2, thereby hindering the phosphorylation of the retinoblastoma protein
(pRb) and preventing the S-phase entry.
In the present study, we found that Cdk6 level was reduced by TGF-ß in a time-
and dose-dependent manner, and that overexpression of Cdk6 circumvented TGF-ß
growth arrest. Ectopic Cdk6 was shown to sequester the TGF-ß-induced-p15 Cdk
inhibitor and prevent the shift of p27 Cdk inhibitor from Cdk6 to Cdk2. This resulted
in the accumulation of active Cdk6- and Cdk2-associated complexes and allowed the
S-phase entry in the presence of TGF-ß. The findings suggest that the downregulation
of Cdk6 is crucial for TGF-ß-mediated cell cycle arrest.
Several components of the TGF-ß signal transduction pathway and regulators of
G1/S cell cycle transition are degraded through the proteasome system. In our study,
treatment of cells with proteasomal inhibitors was shown to alter TGF-ß signaling in a
gene-specific manner and to abolish the antimitogenic effect of TGF-ß, indicating that
proteasomal activity is required for proper TGF-ß signal transduction and TGF-ß
growth inhibition program.
 Though normal mammary epithelial cells are sensitive to TGF-ß-mediated growth
arrest, breast cancer cells are usually refractory to this effect. In an attempt to define
the defects of TGF-ß signaling in breast cancer, we analyzed the expression of a
newly identified TGF-ß signaling inhibitor, SnoN (Ski-related novel protein N) in
1122 human breast cancer specimens.  SnoN was found to be expressed in a specific
pattern in breast carcinoma tissues and a reduced SnoN protein level indicated a better
outcome in breast cancer patients.
In summary, the present study gives further insights into the molecular
mechanisms of TGF-ß-induced G1 cell cycle inhibition. The proper function of TGF-
ß requires downregulation of Cdk6, as well as the intact activity of the proteasome.
The in vivo study suggests that a TGF-ß signaling inhibitor, SnoN, can serve as a
prognostic marker in breast cancer patients.
REVIEW OF THE LITERATURE
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REVIEW OF THE LITERATURE
1. Signal transduction by transforming growth factor-ß
The transforming growth factor-ß (TGF-ß) superfamily of growth factors
comprises about 40 members which fall into several subgroups called TGF-ß isoforms
(TGF-ß1, -2 and -3), activins, bone morphogenetic proteins (BMPs), and growth and
differentiation factors (GDFs) (reviewed by Kingsley, 1994; Robert and Sporn, 1996;
Massagué, 1998). Transforming growth factor-ß1 (TGF-ß1) was originally isolated as
one of two components (TGF-α and -ß) that could induce a transformed phenotype in
normal rat kidney fibroblasts, but subsequently TGF-ß1 was found to be growth
inhibitory to certain cells (Roberts et al., 1981; Derynck et al., 1985). Soon it became
clear that the biological function of TGF-ß1 was not restricted to regulation of cell
growth but was also involved in many other cellular processes (reviewed in Massagué
1998; Akhurst and Derynck, 2001). Expressed in tissue-specific patterns and complex
contexts, TGF-ß1 and its two mammalian isoforms, TGF-ß2 and TGF-ß3, regulate
numerous biological activities such as regulation of cell proliferation, extracellular
matrix (ECM) production, angiogenesis, and immunomodulation (reviewed by
Dennler et al., 2002). Aberrant expression and function of TGF-ßs and their signal
transducers have been associated with cancers, fibrosis, vascular disorders, and
autoimmune diseases (reviewed in Roberts and Sporn, 1990; Hartsough and Mulder,
1997; Dennler et al., 2002). These diverse activities have prompted intense
investigation into how the TGF-ßs signal their effects.
 TGF-ß1 (hereby TGF-ß) is secreted from cells as a latent complex which can later
be activated by proteases and binding proteins (Kanzaki et al., 1990; Tsuji et al.,
1990; reviewed by Lawrence, 2001). The active ligand transduces its signal mainly
through the receptor-Smad pathway (reviewed in Massagué 1998; Massagué 2000;
Massagué and Chen, 2000; Massagué and Wotton, 2000; Attisano and Wrana, 2002;
ten Dijke et al., 2002) (Fig. 1).
1.1 TGF-ß receptors
TGF-ß type I and type II receptors are transmembrane serine/threonine kinases
(Cheifetz et al., 1987; Boyd and Massagué, 1989). They have an extracellular domain
that is rich of cysteine residues, a transmembrane domain, and an intracellular
serine/threonine kinase domain. The type II receptor kinase is a constitutively active
kinase, whereas the type I receptor kinase needs to be activated by the type II receptor
kinase. In the absence of TGF-ß, the type I and II receptors exist as monomers. In
response to ligand binding, the type II receptors bind to the type I receptors and
phosphorylate their cytoplasmic domains in a region rich of glycine and
serine/threonine residues (termed the GS domain) (Attisano et al., 1993; Franzen et
al., 1993). This phosphorylation changes the conformation of the type I receptors,
thereby allowing them to phosphorylate specific intracellular proteins and propagate
the TGF-ß signal into cells. To date, seven distinct type I receptors have been
identified, each of which matches with one of the five type II receptors to mediate
signals for distinct TGF-ß family ligands. Three of the type I receptors transduce
TGF-ß/activin signals (Franzen et al., 1993; Wrana et al., 1994; Oh et al., 2000). In
addition to the type I and type II receptors, TGF-ß can also bind to receptor-associated
transmembrane proteins, such as betaglycan (also called TGF-ß receptor type III) and
endoglin (Cheifetz et al., 1992; Lopez-Casillas et al., 1993). These proteins have no
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intrinsic enzymatic activity but have been shown to modulate TGF-ß signaling.
Betaglycan may facilitate the binding of TGF-ß to the type II receptor  (Lopez-
Casillas et al., 1993), whereas the mechanism by which endoglin affects TGF-ß
signaling is still unclear.
Both type I and type II TGF-ß receptors have been found to be mutated in some
human cancer cells (reviewed by Massagué, 1998). Mutation of type II receptor was
first reported in certain human colon cancers refractory to the growth inhibitory
effects of TGF-ß (Markowitz et al., 1995), and afterwards was found specifically in
gastrointestinal cancers (Myeroff et al., 1995; Parsons et al., 1995). Type I receptor
mutations in human cancers have also been identified in pancreatic cancer,
lymphoma, and cervical cancer (Goggins et al., 1998; Chen et al., 1999; Pasche et al.,
1999; Schiemann et al., 1999).
Fig 1. Schematic representation of the TGF-ß signal transduction pathway by receptor-Smad. Ligand
binding leads to the activation of TGF-ß receptor complex (TßR), which phosphorylates and activates
the Smad2/3. After phosphorylation, Smad2/3 associates with Smad4, and migrates into the nucleus
where they either bind directly to DNA or associate with other transcription factors to regulate the
transcription of a large number of genes. Smad7 antagonizes TGF-ß signaling by intefering the activity
of the receptor complex. Adapted from Massagué 1998; Massagué 2000; Massagué and Chen, 2000;
Massagué and Wotton, 2000; Attisano and Wrana, 2002; ten Dijke et al., 2002. P, phosphorylation.
    Smad7
transcription
TGF-ß
TßR
Smad4
Smad2/3
P
Smad4
Smad2/3
P
Smad2/3
Smad4
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P
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1.2 Transduction of  TGF-ß signals by Smad proteins
1.2.1 Function of Smad proteins in TGF-ß signal transduction
Smad (Sma/Mad related mothers against dpp) proteins were first identified as
products of the Drosophila Mad and C. elegans Sma genes, and this family has
quickly grown to include eight mammalian counterparts which fall into three distinct
classes based on their structures and functions in the signal transduction pathway
(Sekelsky et al., 1995; Savage et al., 1996; reviewed in Riggins et al., 1996; Heldin et
al., 1997; Massagué, 1998).
The receptor-activated Smads, or R-Smads (Smad2 and -3 for TGF-ß), were the
first substrates identified for the TGF-ß type I receptor. Smad2 and Smad3 can be
directly phosphorylated by the receptor at the C-terminus (Macias-Silva et al., 1996).
The phosphorylation induces changes in the protein structures and facilitates the
release of Smads from the receptor complexes as well as from SARA (Smad anchor
for receptor activation), the protein recruits Smads to the membrane. Afterwards, the
phosphorylated R-Smads form heteromeric complexes with a co-Smad, Smad4, and
migrate into the nucleus, where they modulate gene transcription (Zhang et al., 1996;
Lagna et al., 1996; Shi et al.,1997; Wu et al., 1997; reviewed in Massagué and
Wotton, 2000; Yue and Mulder 2001). Smad proteins have not enzymatic activity but
rather exert their functions through protein-DNA and protein-protein interactions.
They either associate directly with DNA or with transcription factors, thereby
positively or negatively regulating gene expression  (Chen et al., 1996; Macias-Silva
et al., 1996; Liu et al., 1997; Dennler et al., 1998). Inhibitory Smads (I-Smads, Smad7
for TGF-ß), attenuate TGF-ß signaling by competing with R-Smads for receptor
interaction and by targeting receptors to the proteasome-dependent degradation. The
expression of Smad7 itself can be induced by TGF-ß, thus exerting a negative
feedback to TGF-ß effect (Abdollah et al., 1997; Imamura et al., 1997; Tsuneizumi et
al., 1997; Hata et al., 1998; Hanyu et al., 2001; Liu et al., 2002).
In addition to regulating transcription, Smads can also control the turnover of
certain proteins. Smad2/3 serve as adaptors to bring ubiquitin E3 ligases (proteins
which ligate ubiquitins to substrate proteins. For details see Review of the Literature
3.1.2), such as Smurfs and the anaphase-promoting complex (APC), to protein
substrates like Ski-related novel protein N (SnoN), and target their degradation via
proteasome (Sun et al., 1999; Bonni et al., 2001; Wan et al., 2001; Attisano and
Wrana, 2002). Smad7 is also able to induce the proteasome-dependent degradation of
the receptor by recruiting Smurf2 ubiquitin E3 ligase to the receptor complex (Kavsak
et al., 2000). For details see section 3.2 of the Review of the Literature.
1.2.2 Regulation of the functions of R-Smads
As the R-Smads are the basic components of the core intracellular signaling
cascade of TGF-ß, their localization, activities, and abundance are tightly controlled.
Subcellular localization of R-Smads is directly related to their activation and
function. In the absence of TGF-ß, R-Smads exist in both cytoplasm and nucleus.
Upon TGF-ß stimulation, they are brought to the cell membrane by anchor proteins
like SARA, in which they are phosphorylated by the type I receptor (Wu et al., 2000).
Phosphorylation reduces the affinity of R-Smads toward SARA and enhances the
affinity of R-Smads toward Smad4, thus facilitating activated R-Smads to associate
with Smad4 and enter the nucleus (Xu et al., 2002). The phosphorylated R-Smads in
the nucleus are being constantly dephosphorylated and dissociated from Smad4. The
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inactive R-Smads then migrate to cytoplasm, where they can be reactivated by active
receptors and return to the nucleus, or they accumulate in cytoplasm if the receptor is
no longer active (Inman et al., 2002).
The activities of R-Smads are negatively regulated by Sloan-Kettering Institute
protein (Ski) and its closely related homolog SnoN protein. Ski and SnoN directly
associate with Smads and inhibit their capabilities of transactivation via recuiting
histone deacetylase (HDAC) to Smads (reviewed by Liu et al., 2001). For details, see
Review of the Literature 1.5.
Termination of the function of activated R-Smads is crucial for controlling the
extent of TGF-ß effects. Dephosphorylation is suggested to be carried out by
unidentified phosphatases in the nucleus and to contribute to the dissociation of Smad
complexes (Inman et al., 2002). Degradation of R-Smads is enforced partially through
the ubiquitin-proteasome pathway (for details see Review of the Literature 3.2).
Deregulation of Smad function has been associated with certain diseases. For
example, tumor cells target the Smad pathway to escape from TGF-ß-induced growth
inhibition. Deletions or inactive mutations of Smad2 have been reported in cancers
from the pancreas, colon, head, neck, and lung (Riggins et al., 1996; Takagi et al.,
1998; Miyaki et al., 1999).
1.3 Non-Smad pathways transducing TGF-ß signals
Although Smads are the core of TGF-ß signaling, accumulating evidence suggests
that Smad-independent pathways also exist. For example, TGF-ß receptors can
activate phosphatidylinositol 3-kinase (PI3-kinase) and the small GTP-binding protein
RhoA (Bakin et al., 2000; Bhowmick et al., 2001). In addition, mitogen-activated
protein kinases (MAPK, including ERK, p38, and JNKs) and protein kinase B (PKB)
are also found to be activated by TGF-ß (Engel et al., 1999; Zavadil et al., 2001). It
remains unclear, however, how these pathways are connected to receptor activation
and how they contribute to the biological effects of TGF-ß.
1.4 Crosstalk between TGF-ß and other signaling pathways
Cells are always exposed to a complicated environment, receiving multiple
extracellular signals. Depending on the state of the cells and the intensities of the
signals, cells integrate different signaling cascades and make decisions concerning
their reactions. One factor influencing the fate of cells is the crosstalk between TGF-ß
anti-mitogenic signaling and Ras mitogenic signaling. In normal epithelial cells, TGF-
ß can override the proliferative effects of EGF and other Ras-activating mitogens,
leading to growth arrest (Massagué 1990; Alexandrow and Moses, 1995). Cells
transformed by Ras, however, are resistant to TGF-ß-mediated growth inhibition
(Chen et al., 2001). Ras has been shown to reduce the expression of TGF-ß receptor
and Smad4, and affect the nuclear localization of Smad4 (Saha et al., 2001).
1.5 Regulation of TGF-ß signaling by SnoN
1.5.1 Diverse functions of SnoN in mammalian cells
Sno (Ski-related novel gene) is a member of the ski proto-oncogene family that was
found by probing human cDNA libraries using v-Ski, the transforming protein of the
Sloan-Kettering virus (Nomura et al., 1989). Although there is only one form of Sno
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(SnoN) in chicken, and two isoforms (SnoN and SnoN2) in mice, several human
isoforms of Sno (designed as SnoA, SnoN, SnoN2, and SnoI) have been reported
(Nomural et al., 1989; Pearson-White et al., 1993; Pearson-White and Crittenden,
1997). Human SnoN is a 80 kDa protein of 684 amino acids (Nomural et al., 1989).
SnoN shares 37% overall identity with the Ski protein, and these two proteins contain
a region highly conserved. Overexpression of SnoN leads to transformation of
chicken and quail embryo fibroblasts as well as muscle differentiation of quail
embryo cells (Boyer et al., 1993). Both transformation and differentiation functions
require the N-terminal portion of SnoN (Cohen, 1998; Nomura et al., 1999), which is
highly homologous to c-Ski and v-Ski (Nomura et al., 1989). Mice lacking Sno die at
an early stage of embryogenesis, and Sno+/- heterozygous mice are hypersensitive to
chemical carcinogens and develop spontaneous lymphomas at higher frequencies
(Shinagawa et al., 2000), suggesting that Sno may act as a tumor suppressor (rather
than an oncogene) in some types of cells. The diverse functions of SnoN may be due
to its nature of the transcription regulator (Nomura et al., 1999).
1.5.2 Regulation of TGF-ß signaling by SnoN
Even though Ski and SnoN appear to be able to transform cells and function in
tumorigenesis, they received little attention in the past. This changed in 1999, when
several investigators searched for new components of the Smad-associated proteins.
Using diverse approaches, they identified Ski and SnoN as Smad 2/3/4-associated
proteins, negatively regulating TGF-ß signaling (Akiyoshi et al., 1999; Stroschein et
al., 1999; Sun et al., 1999a). These findings immediately placed Ski/SnoN in one of
the hottest research areas (Vogel, 1999). In 293T cells co-transfected with various
Smad proteins and SnoN, SnoN coprecipitates with Smad2, Smad3 or Smad4, but not
with Smad1 or Smad5 (Stroschein et al., 1999). Binding of SnoN to Smad2 and
Smad3 requires the N-terminal 96 amino acids of SnoN, and the residues 138 to 255
in SnoN mediate the interaction with Smad4 (Stroschein et al., 1999). Binding of c-
Ski to Smad2/3 causes dissociation of p300 from the Smad2/3 complex, which results
in a reduction in histone acetyltransferase (HAT) activity of the Smad2/3 complex
(Akiyoshi et al., 1999). Additionally, Ski/SnoN also recruits the transcription complex
N-CoR/mSin3A to the Smad complex, and N-CoR/mSin3A in turn associates with
HDAC, promoting histone deacetylation and repressing TGF-ß signaling (Stroschein
et al., 1999) (Fig. 2). Overexpression of the Sno family of proto-oncogenes interferes
with TGF-ß signaling and causes cells to become refractory to the anti-proliferative
activity of TGF-ß (Sun et al., 1999b), suggesting a potential mechanism for
Ski/SnoN-mediated oncogenesis.
A study of Ski expression in human melanoma suggests that Ski localizes in the
nucleus as well as in cytoplasm in vivo, and that the localization of Ski changes from
the nucleus in melanoma in situ, to the nucleus and cytoplasm in primary and
metastastic melanoma (Reed et al., 2001). Furthermore, their in vitro study shows that
the association of Ski/Smad in the cytoplasm may prevent the nuclear entry of Smad
complexes, indicating another pathway by which Ski/SnoN block TGF-ß signaling
(Reed et al., 2001). This is corroborated by structural analysis of Ski interaction with
Smad4 which suggests that Ski/SnoN blocks the interaction between Smad4 and R-
Smads (Wu et al., 2002). Accordingly, the Ski/SnoN proteins in the nucleus directly
interfere with Smad transcriptional activity, and the Ski/SnoN proteins in the
cytoplasm may play a role in preventing the formation of Smad complexes and their
entry to the nucleus. The factors affecting the subcellular localization and thus the
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function of Ski/SnoN are not yet clear.
Fig. 2. Regulation of TGF-ß
signaling by Ski/SnoN. Ski/SnoN
associates directly with the
Smad2/3-Smad4 complex and
recruits the transcription co-
repressor N-CoR/ mSin3A to Smad
complex. N-CoR/ mSin3A in turn
interacts with HDAC, which
promotes histone deacetylation and
represses TGF-ß signaling
(Modified from Bonni et al., 2001
and Liu et al., 2001).
1.5.3 Regulation of SnoN by TGF-ß
SnoN negatively regulates TGF-ß signaling and conversely, TGF-ß also shows the
ability to regulate SnoN level. TGF-ß treatment leads to a rapid and dramatic
reduction in SnoN level. The loss of SnoN can be inhibited by proteasome inhibitors,
suggesting TGF-ß signaling causes proteasome-dependent degradation of SnoN (Sun
et al., 1999b; Bonni et al., 2001; Wan et al., 2001). Reduction of SnoN in response to
TGF-ß is predicted to relieve the repression of SnoN on Smad complexes and allow
the TGF-ß signal to be transduced.
SnoN contains a destruction box (D-box) at its N-terminus, one of two sequence
elements either of which is present in all anaphase-promoting complex (APC)
substrates discovered to date (Wan et al., 2001). Further studies have confirmed that
APC is the E3 ubiquitin ligase for SnoN degradation via the proteasome pathway and
suggested that Smad3 is also involved in this process (Wan et al., 2001). Upon TGF-ß
treatment, Smad3 translocates into the nucleus and recruits the APC to SnoN,
inducing subsequent ubiquitination of SnoN in a D-box-dependent manner. In
addition to the D-box, efficient ubiquitination and degradation of SnoN also requires
the Smad3 binding site in SnoN as well as key lysine residues necessary for ubiquitin
attachment. Mutation of either the Smad3 binding site or the lysine residues results in
stabilization of SnoN and antagonism to TGF-ß signaling (Wan et al., 2001). Besides
Smad3, Smad2 can also induce SnoN degradation through recruitment of Smurf2
ligase to SnoN protein in respond to TGF-ß treatment. Two elements in SnoN protein
are essential for this action: one is the first 96 amino acids of the protein and another
is a region in the C-terminus. A SnoN mutant lacking either of these regions is
resistant to Smad2-Smurf2-mediated degradation (Bonni et al., 2001). It is unclear
how Smad2-Smurf2 and Smad3-APC pathways cooperate in mediating the turnover
of SnoN.
These studies elucidate important mechanisms of TGF-ß-induced degradation of
SnoN. Interestingly, Luo group (Stroschein et al., 1999) showed that in Hep3B cells, a
2 h exposure to TGF-ß results in an increase in SnoN level due to the enhanced SnoN
mRNA level, and this effect lasted till 24 h after the treatment with TGF-ß (Stroschein
et al., 1999). This effect may allow SnoN to interfere with the activities of the Smad
complexes at late timepoints and exert a negative feedback loop to limit the extent of
the TGF-ß signaling (Stroschein et al., 1999).
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On the basis of these findings, a model of the regulation of TGF-ß signaling by
SnoN has been suggested. In the absence of TGF-ß, SnoN binds to the nuclear Smads
and represses their transactivation capabilities through recruitment of a nuclear
repressor complex to Smads. TGF-ß treatment induces the activation and nuclear
translocation of Smad2/3/4 complexes, which causes degradation of SnoN through the
proteasome, hence relieving SnoN repression and allowing Smads to regulate the
expression of TGF-ß-responsive genes. At a later stage, TGF-ß induces the expression
of SnoN transcriptionally, which eventually turns off the signal transduction, limiting
the extent of TGF-ß responses (Stroschein et al., 1999).
2 G1/S cell cycle phase transition and its regulation by TGF-ß
2.1 Regulation of mammalian cell division cycle by cyclin-dependent kinases
The mammalian cell division cycle is a set of events that governs the self-
replication of the cell. The cycle is divided into four phases: the synthesis (S) phase,
in which the chromosome is faithfully duplicated; the mitosis (M) phase, in which all
of the cellular material is divided into two identical daughter cells; and two gap (G1
and G2) phases between the S and M phases, in which the cells grow and prepare the
material for the entry and the completion of S and M phases. In unfavorable
environments, the cell stops cycling and enters the quiescent G0 phase, from which it
can reenter the cycle through the G1-phase when environmental cues permit (Pardee,
1989; Sherr, 1993; Grana and Reddy, 1995; Nurse, 2000) (Fig. 3).
Fig. 3 The mammalian cell division cycle. The
cell goes through the G1-, S-, G2- and M-phase of
a cell cycle to replicate itself and divide into two
daughter cells. G0 is a quiescent stage when the
cell faces unfavorable conditions and stops the
cycle. R point, restriction point (Pardee, 1989;
Sherr, 1993; Grana and Reddy, 1995; Bartek et
al., 1996; Nurse, 2000; Blagosklonny and Pardee,
2002). (Adopted from Sherr, 1993.)
The transitions of the cell cycle phases are tightly controlled, and the next phase
will not start until the previous one has been successfully completed, thereby
guaranteeing that the genetic material is correctly copied only one time in one cycle
(Grana and Reddy, 1995; Nurse, 2000). The cell cycle progression is controlled by
kinase complexes consisting of a cyclin-dependent kinase (Cdk) subunit and a cyclin
subunit (Evans et al., 1983; Minshull et al., 1989). While in yeast only a single Cdk
exists, higher eukaryotes including mammals have nine Cdks, as well as a diversity of
mammalian cyclins, regulating cell cycle progression as well as other cellular events.
Transitions between different phases in the cell cycle are driven by sequential
activation and inactivation of various Cdks in complexes with cyclins (Carnero, 2002)
(Table 1).
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Table 1. Function of mammalian cyclin-dependent kinase (Cdk) complexes
Cdk            Regulatory subunit          Substrate                            Function
Cdk1 cyclin A, B pRb, NF, histone H1 G2/M
Cdk2 cyclin A, E pRb, p27, histone H1 G1/S, S
Cdk3 cyclin E E2F1 G1/S
Cdk4 cyclin D1, D2 & D3 pRb G1/S
Cdk5 cyclin D1 & D3, p35 NF, Tau Neuronal differentiation
Cdk6 cyclin D1, D2 & D3 pRb  G1/S
Cdk7 cyclin H, MAT1 Cdk1, Cdk2/4/6 Cdk-activating kinase
Cdk8 cyclin C RNA Pol II Transcription regulation
Cdk9 cyclin T pRb, MBP G1/S
: modified from Carnero, 2002.
The progression from the G1- to S-phase is a key regulation point during the cell
cycle. Cells converge the mitogenic and anti-mitogenic signals at the restriction (R)
point in the late G1-phase, and make the decision whether to continue the cycle or
not. Once the cells pass through the R point, they no longer require the extracellular
mitogenic signals to complete the cycle (Bartek et al., 1996; Blagosklonny and
Pardee, 2002) (Fig. 3). The Cdks controlling G1/S transition are Cdk4, Cdk6, and
Cdk2, in complexes with cyclin D and cyclin E, respectively (Reed, 1997; Ekholm
and Reed, 2000). To ensure the proper progression of cell cycle from the G1-phase to
the S-phase, the activities of Cdk4, Cdk6, and Cdk2 must be tightly regulated. Their
cellular levels tend to remain constant throughout the normal cell cycle, and the
regulation of catalytic activity is primarily post-translational. The biochemical
mechanisms involved in the regulation of Cdk activity include activation by cyclins
and CAK phosphorylation, and inhibition by phosphorylation and specific Cdk
inhibitors as detailed below (reviewed by Morgan, 1995; Vidal and Koff, 2000). The
most studied substrates of Cdk4, Cdk6, and Cdk2 have been the retinoblastoma
protein (pRb) and its related family members, p107 and p130 (reviewed in Adams,
2001).
2.2 Function of Cdk4, Cdk6, and Cdk2 during G1/S progression
Cdk4, Cdk6 and Cdk2 collaborate to trigger the G1/S progression in complexes
with cyclin D and cyclin E, respectively. The well-accepted model is that during the
G1/S progression, Cdk4, Cdk6, and Cdk2 phosphorylate pRb in a progressive multi-
step manner, and fully phosphorylated pRb librates E2F transcription factor, which
induce the expression of genes required for S-phase entry (reviewed by Dyson 1998;
Nevins, 1998) (For details see Review of the Literature 2.3).
Cdk4 and Cdk6 share 71% identity in amino acid sequence (Meyerson et al.,
1992). Cdk4 null mice present with smaller body size, reduced fertility, and insulin-
dependent diabetes (Rane et al., 1999; Tsutsui et al., 1999). The lack of other obvious
defects may be due to the compensation by Cdk6. The phenotype of Cdk6 null mice
has not been published yet. Whereas Cdk4 is preferentially expressed in mesenchymal
cells, Cdk6 is ubiquitous in hematopoietic cells (Meyerson et al., 1992). Both Cdk4
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and Cdk6 form active complexes with cyclin D (Meyerson and Harlow, 1994).
Though Cdk4 mutations and amplifications are found in human tumors (Hall and
Peters, 1996), alterations in Cdk6 are less reported, with a mutation in its binding
domain to a small molecular weight inhibitor, p16, found in one neuroblastoma cell
line (Easton et al., 1998). Cdk4 and Cdk6 share at least one substrate, pRb, and target
the same sites (Kitagawa et al., 1996), but it is not clear whether Cdk6 will fully
compensate for the function of Cdk4 in all cells (Tsutnui et al., 1999; Oreaga et al.,
2002). Furthermore, in NRK cells which express both Cdk4 and Cdk6, only Cdk4 is
essential for the cell cycle start stimulated by serum (Jinno et al., 2001), suggesting a
difference between Cdk4 and Cdk6 functions.
Associated with cyclin E, Cdk2 is shown to complete the phosphorylation of pRb
initiated by Cdk4 and Cdk6. In contrast to D-type cyclin-Cdk complexes, the cyclin
E-Cdk2 complex has a broad range of substrates. Besides pRb, it can also
phosphorylate histone H1 (Koff et al., 1991; Dulic et al., 1992; Koff et al., 1992), the
Cdk inhibitor p27Kip1 (Sheaff et al., 1997; Vlach et al. 1997), and possibly other
substrates that help to trigger the S-phase entry (Blow and Nurse 1990; Fang and
Newport 1991; Stillman 1996; Krude et al. 1997; Zhao et al., 1998).
2.2.1 Activation of Cdks by cyclins
The cyclins controlling the G1/S-phase transition include D-type cyclins (cyclin
D1, D2 and D3) which form complexes with Cdk4 and Cdk6, and E-type cyclins
(cyclin E and E2) which are in complex with Cdk2. Although cyclin D activity is
required for S-phase entry in pRb positive cells, it is dispensable in pRb negative cells
(Lukas et al., 1995; Medema et al., 1995). Cyclin E is, however, required in both pRb
positive and negative cells (Ohtsubo et al., 1995). Ectopic expression of both types of
cyclins shortens the G1-phase (Ohtsubo and Robert, 1993; Quelle et al., 1993),
indicating that they are rate-limiting factors in G1/S-phase progression. When
coexpressed, however, they shorten the G1-phase even further than when expressed
alone (Ohtsubo and Roberts, 1993; Quelle et al., 1993). This suggests that they
regulate overlapping, yet also distinct, events.
2.2.1.1 D-type cyclins
The three D-type cyclins (D1, D2 and D3) are expressed in a cell type-specific and
overlapping manner (Sherr, 1993; Grana and Reddy, 1995). A study from “single
cyclin D”-expressing mouse model suggests that in these mice, the tissue-specific
expression pattern of cyclin Ds is lost, and the functions of the cyclin Ds are largely
exchangeable in the early stage but not in later life (Ciemerych et al., 2002). In
contrast to other cyclins, the levels of cyclin Ds do not oscillate abruptly during the
cell cycle and show only a modest peak in late G1-phase. Cyclin D performs two
known functions in complexes with Cdk4/6 during G1/S transition. One is to
phosphorylate pRb, and the other is to sequester Cdk inhibitors of the Cip/Kip family.
Both of these functions have the effect of activating cyclin E, the first by inducing
E2F-mediated cyclin E gene transcription, and the second by reducing the inhibitory
threshold imposed by the pool of free Cdk inhibitors in the cell. Besides these two
effects, cyclin D1 has been shown to have a Cdk-independent function as a co-
activator of the estrogen receptor (ER) (Zwijsen et al., 1997). It has been suggested
that this interaction may contribute, in part, to the hypoplasia of the mammary
epithelium in cyclin D1 knockout mice, and perhaps leads to hyperplasia of mammary
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cells in human tumors overexpressing cyclin D1 (Zwijsen et al., 1997).
D-type cyclins are sensitive to mitogenic signals and act as growth factor sensors.
Mitogenic Ras signaling can promote transcription of the cyclin D1 gene (Filmus et
al., 1994; Albanese et al., 1995; Lavoie et al., 1996; Winston et al., 1996; Aktas et al.,
1997; Kerkhoff and Rapp, 1997; Weber et al., 1997). Ectopically expressed cyclin D
does not efficiently associate with Cdks in the absence of mitogenic signals
(Matsushime et al., 1994). Turnover of D-type cyclins relies on the phosphorylation
of a single threonine residue (Thr286) by glycogen synthase kinase-3ß (GSK-3ß),
while Ras signaling negatively affects this process through the action of
phosphatidylinositol 3-kinase (PI3K) and PKB (Diehl et al., 1998). Hence, every step
of activation of cyclin D, the expression, assembly with Cdks, and turnover, is
mitogen-dependent.
2.2.1.2 E-type cyclins
In contrast to D-type cyclin, cyclin E is expressed in all of the cell types, and the
assembly of cyclin E and Cdk2 into an active kinase is not mitogen-dependent. In
most cells, the levels of cyclin E mRNA and protein rise dramatically in mid-to-late
G1 when pRb undergoes phosphorylation (Koff et al., 1991; Weinberg, 1995).
Overexpression of cyclin E in human osteosarcoma cells causes pRb phosphorylation
(Hinds et al., 1992; Weinberg, 1995). Besides this, several lines of evidence clearly
indicate that cyclin E-Cdk2 has other unique functions in addition to phosphorylation
and inactivation of pRb, and may trigger the actual onset of DNA replication once
cells pass the restriction point (reviewed by Sherr and Roberts, 1995).
A study of cyclin E-replacing-cyclin D1 mouse model gives interesting results. In
these mice, cyclin D1 genomic coding sequences is replaced with those encoding
cyclin E, and cyclin E protein is expressed with the correct developmental timing and
tissue specificity of cyclin D1 (but there is no longer any cyclin D1 expression, and
the normal cyclin E gene is still present in these mice, and its expression is unaffected
by the new cyclin E  D gene) (Geng et al, 1999). In this model, all known defects
of the cyclin D1 knockout mouse are rescued, and the new phenotype is associated
with ectopic expression of cyclin E. Further analysis of pRb phosphorylation and
Kip/Cip sequestration has suggested that cyclin D1 function is bypassed but not
replaced by the ectopic expression of cyclin E. This study suggests that cyclin D1
function cannot be replaced by cyclin E, but overexpression of cyclin E activates the
cell cycle at downstream steps, therefore bypassing the requirement for cyclin D1
(Geng et al, 1999).
Several groups independently discovered a second cyclin E family member, cyclin
E2 (Lauper et al., 1998; Zariwala et al., 1998; Gudas et al., 1999). The cyclin E2
protein shares 47% overall similarity with cyclin E, and can associate with Cdk2 in a
functional, catalytically active kinase complex phosphorylating histone H1 and pRb.
Cyclin E2 is also able to form a complex with Cdk3, but the function of this
interaction is unclear (Zariwala et al., 1998). Ectopic expression of cyclin E2 in
human cells accelerates the G1-phase (Gudas et al., 1999). The regulation of cyclin
E2 is similar to that of cyclin E: its transcription is induced after the phosphorylation
of pRb, and its kinase activity is inhibited by the association with p21 or p27 (Lauper
et al., 1998).
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2.2.2 Activation of Cdks by CAK
Complete activation of Cdks requires the phosphorylation at a conserved threonine
residue (Thr161 in human Cdk1 and Thr160 in Cdk2) by a Cdk-activating kinase
(CAK). CAK is a multimeric enzyme composed of cyclin H, Cdk7, and MAT1 (Desai
et al., 1992; Fisher and Morgan, 1994; Devault et al., 1995; Fisher et al., 1995;
Tassan et al., 1995). Phosphorylation of Cdks by CAK is favored by cyclin
association. Binding to cyclin induces a significant change in the structure of Cdk and
further exposes the threonine residue, making it more accessible to CAK.
Phosphorylation by CAK may also serve to stabilize the cyclin-Cdk complex
(reviewed by Kaldis, 1999).
2.2.3 Inhibitory phosphorylations of Cdks
Cdks are negatively regulated by phosphorylation of residues within the ATP-
binding pocket (Thr14 and Tyr 15 in human Cdk1 and Cdk2). In Cdk2, the side-
chains of these residues hang from the ceiling of the ATP-binding site and are in a
position to affect kinase activity when phosphorylated. Mutation in either Tyr15 or
Thr14/Tyr15 stimulates Cdk2 kinase activity (Gu et al., 1992). The kinase responsible
for the phosphorylation on Tyr15 is thought to be Wee1, originally identified in S.
pombe, and the one for Thr14 is unclear. Thr14 and Tyr15 are both dephosphorylated
by a Cdc25 phosphatase family which includes Cdc25A, Cdc25B and Cdc25C (Gu et
al., 1992; Morgan, 1995; Nilsson and Hoffmann, 2000). In an in vitro study, Cdc25 is
reported to dephosphorylate Cdk2 on Thr14 and Tyr15 and increase Cdk2 kinase
activity by 4-fold (Gu et al., 1992). Cdk4 and Cdk6 have only tyrosine in this region
(Matsushime et al., 1992; Meyerson et al., 1992) and are phosphorylated in UV- or
TGF-ß treatment of cells (Terada et al., 1995; Iavarone and Massagué 1997).
2.2.4 Inhibition of Cdks by Cdk inhibitiors
The activities of cyclin D- and E-dependent kinases are negatively regulated by
two structurally unique families of Cdk inhibitors (CKIs): the Cip/Kip (Cdk
interacting protein/kinase inhibitory protein) family, which is composed of three
members, p21Cip1 (hereby p21, el-Deiry et al., 1993; Harper et al., 1993), p27Kip1
(hereby 27, Koff et al., 1993; Polyak et al., 1994; Toyoshima and Hunter, 1994), and
p57Kip2 (hereby p57, Lee et al., 1995; Matsuoka et al., 1995); and the Ink4
(inhibitors of Cdk4) family, including p16Ink4a (hereby p16, Serrano et al., 1993),
p15Ink4b (hereby p15, Hannon and Beach, 1994), p18Ink4c (hereby p18, Guan et al.,
1994; Hirai et al., 1995), and p19Ink4d (hereby p19, Chan et al., 1995; Hirai et al.,
1995; for review see Sherr and Roberts, 1999). The CKIs associate directly with the
Cdk and/or cyclin subunits and inhibit their activities (Arellano and Moreno, 1996;
Lee and Yang, 2001).
2.2.4.1Cip/Kip family
Cip/Kip proteins share conserved region that enables them to interact with both
cyclin and Cdk (Chen et al., 1995, 1996b; Nakanish et al., 1995; Lin et al., 1996;
Russo et al., 1996), affecting the activities of all of the cyclin D- , E-, and A-
dependent kinases. A crystal structure study has revealed details of the mechanism:
the association of p27 with the cyclin A-Cdk2 complex leads to a change in the
conformation of Cdk2, hinders ATP binding, and blocks phosphorylation by CAK,
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thus inactivating Cdk2 kinase activity (Russo et al., 1996).
Although Cip/Kip proteins are inhibitors for E- and A-type cyclin-Cdk complexes,
a large number of studies have suggested their positive functions in regulation of
cyclin D-dependent kinases. The Cip/Kip family is required for proper formation and
function of cyclin D-Cdk complexes. This was first demonstrated by LaBaer et al.
(1997), who reported that both p21 and p27 promoted interactions between D-type
cyclins and their Cdk partners (LaBaer et al., 1997). In a later complementary study,
Cheng et al. (1999) observed that the assembly of cyclin D1/D2-Cdk4 complexes was
impaired in primary mouse embryo fibroblasts (MEF) taken from embryoes lacking
the p21 gene, p27 gene, or both. Reintroduction of p21 or p27 into these cells restored
the formation of cyclin D-Cdk4 complex (Cheng et al., 1999). The Cip/Kip proteins
also promote activation of cyclin D-Cdk complexes (Sherr and Roberts, 1999). All of
the cyclin D-Cdk kinase activity towards pRb in proliferating cells appears in
complexes containing Cip/Kip proteins (Soos et al., 1996; Blain et al., 1997; LaBaer
et al., 1997; Cheng et al., 1999). The first direct insight was that p27
immunoprecipitates contained kinase activity towards pRb but not toward histone H1
– the hallmark of cyclin D-dependent kinase activity (Soos et al., 1996). In human
MANCA B cells, complexes fractionated at 150-170 kDa were found to include p27,
cyclin D3, and Cdk6. Immunodepletion of Cdk6 removed the majority of p27-
associated kinase activity, implying that the cyclin D3-Cdk6-p27 complex retained
catalytic activity. Cyclin D1/2-Cdk4/6-p27/p21 complexes of 150-170 kDa recovered
from other mammalian cell types were similarly enzymatically active (Blain et al.,
1997; LaBaer et al., 1997; Mahony et al., 1998; McConnell et al., 1999; Parry et al.,
1999).
Initially, p27 was identified as a Cdk2-inhibitory activity detected in contact-
inhibited or TGF-ß-treated cells (Koff et al., 1993; Polyak et al., 1994a, b), and it was
subsequently purified and cloned in a yeast two-hybrid screen as a cyclin D-Cdk4
interacting protein (Toyoshima and Hunter, 1994). High levels of p27 are found in
quiescent and differentiating cells, whereas its levels are lower in exponentially
growing cells (Nourse et al., 1994; Toyoshima and Hunter, 1994; Hengst and Reed,
1996; Millard et al., 1997). Ectopic expression of p27 results in G1 arrest, and
expression of p27 antisense RNA in the fibroblasts suppresses quiescence (G0 state)
(Toyoshima and Hunter 1994; Rivard et al., 1996). Regulation of p27 is complicated.
The p27 mRNA levels remain constant throughout the cell cycle, whereas protein
levels change - probably due to the regulation of translation and degradation (Pagano
et al., 1995; Hengst and Reed, 1996; Millard et al., 1997; Kolluri et al., 1999). The
subcellular localization of p27 is also regulated (Blain and Massagué, 2002; Liang et
al., 2002; Viglietto et al., 2002; Shin et al., 2002). p27-deficient mice (p27-/-) show
an increase in body size, but do not have increased incidence of malignant tumors
(Fero et al., 1996; Kiyokawa et al., 1996; Nakayama et al., 1996).
p21was the first identified CKI, as a Cdk2-associated protein found in a yeast two-
hybrid screen, and also as a growth inhibitor in senescent cells (Harper et al., 1993;
el-Deiry et al., 1993). Additionally, p21 was biochemically isolated as a cyclin E-
Cdk2-binding protein (Gu et al., 1993; Xiong et al., 1993). Accordingly, p21 is also
called Sdi1 (senescence cell-derived inhibitor) and Waf1 (wild type p53-activated
fragment). p21 is involved in p53-dependent DNA damage-induced G1 arrest. The
amount of p21 increases following exposure to DNA-damaging agents in wild type,
but not in mutant p53-containing cells (el-Deiry et al., 1993, 1994; Dulic et al., 1994).
Additionally, MEFs obtained from p21 null mice fail to arrest completely in response
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to DNA damage. However, p53-mediated apoptosis is intact in p21-/- cells, implying
that p21 is required for p53-induced G1 arrest but not for apoptosis (Brugarolas et al.,
1995; Deng et al., 1995; Macleod et al., 1995). The regulation of p21 is at the
message RNA level, mostly transcriptional (Gartel and Tyner, 1999), but mRNA
stability may also be regulated (Macleod et al., 1995; Wang et al., 2000).
p57 was cloned simultaneously by two groups when they were looking for
homologs of p21 and p27 (Lee et al., 1995) and using a yeast two-hybrid screen
(Matsuoka et al., 1995). p57  maps to the 11p15.5 chromosomal locus and is
rearranged in many tumors. This inhibitor has been linked to Wilms´ tumors and
Beckwith-Wiedemann syndrome (Hatada et al., 1996; Thompson et al., 1996). Like
p27 and p21, overexpression of p57 leads to G1 arrest (Lee et al., 1995; Matsuoka et
al., 1995). Targeted disruption of p57 in mice indicats a role for this CKI in the
control of the differentiation and apoptosis in particular tissues, and suggests that the
function of p57 cannot be compensated by other Cip/Kip Cdk inhibitors (Yan et al.,
1997; Zhang et al., 1997).
2.2.4.2 Ink4 family
Ink4 proteins share a common structural feature – four or five ankyrin repeats
which mediate protein-protein interactions (Serrano et al., 1993; Guan et al., 1994;
Hannon and Beach, 1994; Chan et al., 1995; Hirai et al., 1995; Russo et al., 1998). In
contrast to Cip/Kip CKIs, the Ink4 proteins specifically bind to Cdk4 and Cdk6 at an
area overlapping with the cyclin D-binding site on the Cdks, thus competing with D-
type cyclins for binding to the Cdk partners (Parry et al., 1995, 1999; McConnell et
al., 1999; reviewed by Vidal and Koff, 2000).
Ink4 proteins are expressed in a cell type-specific manner. However, the way in
which their protein levels are controlled is poorly understood, with the exception of
p15, which is induced by TGF-ß and contributes to TGF-ß-mediated G1-phase arrest
(Hannon and Beach 1994; Reynisdottir et al., 1995; Reynisdottir and Massagué
1997). p16 accumulates progressively as cells age, possibly being induced by a
senescence timer (Alcorta et al., 1996; Hara et al., 1996; Palmero et al., 1997; Serrano
et al., 1997; Zindy et al., 1997). p18 and p19 are focally expressed during fetal
development and may play roles in terminal differentiation (Morse et al., 1997; Zindy
et al., 1997a, b; Phelps et al., 1998). Overexpression of Ink4 proteins arrest the cell
cycle in the G1-phase, and their inactivations contribute to the malignant growth of
human tumors (Guan et al., 1994; Koh et al., 1995; Lukas et al., 1995b; Medema et
al., 1995).
2.2.4.3 Functions of CKIs in tumorigenesis
The ability of CKIs to brake cell cycle progression raises the issue that they may be
tumor suppressive. Reduced p27 protein levels have been reported in lung, colon, and
breast cancers and have been related to histological aggressiveness and poor
prognosis (Esposito et al., 1997; Loda et al., 1997). p21-deficient mice develop
spontaneous tumors from hematopoietic, endothelial, and epithelial sources earlier
than do wild type mice (Martin-Caballero, 2001). However, no human tumors have
been found to have lost both alleles of the p27 or p21 gene. Since Cip/Kip proteins
regulate the cell cycle both positively and negatively, complete loss of their function
probably does not favor the tumor progression. p15 null mice develop tumors at a low
incidence (10%) and only after long latency (Latres et al., 2000). p16-deficiency is
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associated with increased incidence of spontaneous and carcinogen-induced cancers
(Sharpless et al., 2001), and disruption of p16 function is common in human cancers
(Merlo et al., 1995; Raus et al., 1998; Esteller et al., 2001). In fact, among all of the
CKIs, both Ink4 and Cip/Kip, only p16 can be classified as a tumor suppressor by the
genetic criteria of LOH (Ruas and Peters, 1998).
2.3 Regulation of G1/S cell cycle progression by pRb-E2F pathway
2.3.1 pRb family
The retinoblastoma protein (pRb) family is composed of three members, pRb,
p107, and p130 (Weinberg, 1995; Adams, 2001). pRb is a 110 kDa nuclear protein of
the retinoblastoma gene product (Weinberg, 1991). Individuals who inherit a mutant
copy of this gene are predisposed to develop childhood retinoblastoma and, in later
life, osteosarcoma. Mutation of this gene is also associated with a number of sporadic
cancers such as small cell lung carcinoma (Goodrich et al., 1993). Studies from cell-
culture experiments and animal models have suggested a complex role of pRb in cell
proliferation, differentiation and survival (reviewed by Weinberg, 1991; Weinberg,
1995; Adams, 2001; Classon and Harlow, 2002).
In the G0- and the early G1-phases, pRb is hypophosphorylated and is functionally
active. It binds to E2F transcription factors, which are heterodimers comprising an
E2F and a DP family member (referred hereafter as E2F), and inhibits the expression
of E2F-responsive genes (Weinberg, 1995; Herwig and Strauss, 1997). From the mid-
to late-G1-phase, pRb becomes gradually phosphorylated. There are 16 potential
serine/threonine phosphorylation sites in pRb targeted by the cyclin-Cdks, which have
distinct effects on the ability of pRb to interact with its various partner proteins (Taya,
1997; Adams, 2001). For example, pRb phosphorylated on Ser780 appears to abolish
its ability to bind to E2F, and the phosphorylation on Ser807 and/or Ser811 prevents
the association with other proteins (Kitagawa et al., 1996; Knudsen and Wang, 1996;
Dyson 1998; Nevins, 1998). After the entry of the cells to S-phase, pRb is maintained
in its hyperphosphoryated inactive state by the cyclin A-Cdk2 complex, which is
responsible for the progression through the S-phase, and cyclin B-Cdk1 complex
during the M phase (Takuwa N and Takuwa Y, 2001). At the end of the M phase, pRb
is abruptly dephosphorylated through the action of protein phosphase-1 and is able to
reset the complex with E2F (Durfee et al., 1993).
During G1/S transition pRb is sequentially phosphorylated by Cdk4, Cdk6, and
Cdk2. The cascade begins with the phosphorylation by cyclin D-Cdk4 and cyclin D-
Cdk6 complexes. This initial phosphorylation induces a change in the structure of the
pRb protein and facilitates its subsequent phosphorylation by the cyclin E-Cdk2
complex. After being fully phosphorylated, pRb liberates E2F and allows it to activate
the expression of target genes (Lundberg and Weinberg, 1998; Harbour et al., 1999)
(Fig. 4). Viral oncoproteins encoded by DNA tumor viruses, including SV40 large T
antigen, adenovirus E1A, and human papilloma virus E7, specifically bind to and
inactivate the hypophosphorylated form of pRb in the absence of Cdk activation,
leading to accelerated cell cycle progression (Laiho et al., 1990; Wang et al., 1991;
Stirdivant et al., 1992).
Two other pRb family members, p130 and p107, are also shown to bind to and
modulate the activity of E2F (Ewen, 1998; Mulligan and Jacks, 1998). In vivo studies
of p107 and p130 have suggested that their functions overlap with one another and
with pRb (reviewed by Classon and Dyson, 2001). There are 22 phosphorylation sites
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of p130 defined in vivo, but their roles in the cell cycle are unclear (Hansen et al.,
2001). p130 may play a role in G0/G1 transition or in maintenance of the quiescent
state, and p107 may act in the late G1- and S-phase (Moberg et al. 1996; Grana et al.,
1998).
2.3.2 E2F transcription factors
E2F transcription factors regulate the expression of genes necessary for DNA
replication, such as cyclin E and cyclin A, as well as the enzymes required for DNA
metabolism and synthesis (reviewed by Adams, 2001). E2F transcription factor is
composed of two proteins, E2F and DP. There are five E2F family members
identified, and pRb preferentially binds to E2F1-4, whereas p107 and p130 appear to
associate mainly with E2F4 and E2F5 (Yamasaki, 1998).
Fig 4. Sequential phosphorylation of pRb by Cdk4, Cdk6, and Cdk2 during the G1/S cell cycle
transition. In the early G1-phase, pRb stays in an active hypophosphorylated state, which allows it to
associate with the E2F transcription factors (E2F1-4 and DP1) and inhibit E2F-induced transcription.
During G1/S transition, pRb is first phosphorylated by cyclin D-Cdk4/6 complexes. This
phosphorylation induces structural changes in pRb protein and facilitates the subsequent
phosphorylation by cyclin E-Cdk2 complex on sites different from Cdk4/6. Fully phosphorylated pRb
releases E2F from the inhibitory association and allows the expression of genes required for S-phase
entry (Lundberg and Weinberg, 1998; Harbour et al., 1999). P: phosphorylation.
2.4 Inhibition of G1/S-phase progression by TGF-ß
2.4.1 Arrest of G1/S-phase transition by TGF-ß
TGF-ß potently inhibits cell growth by interfering with the G1/S transition in
epithelial, endothelial, and hematopoietic cells. Escape from this arrest is a hallmark
of many cancer cells. However, once a cell has passed through the restriction point, it
does not respond to TGF-ß arrest (reviewed by Hocevar and Howe, 1998). In most
cases, this arrest is reversible, but in some cases, it is associated with terminal
differentiation or programmed cell death (Massagué et al., 2000). The early
observation that TGF-ß inhibits the phosphorylation of pRb during G1-phase (Laiho
et al., 1990) pointed out those Cdks phosphorylating pRb as targets of TGF-ß action
and eventually revealed various gene responses suppressing the activity of G1 Cdks.
TGF-ß inhibits the activities of both cyclin D-Cdk4/6 and cyclin E-Cdk2 complexes,
thereby resulting in the hypophosphorylation of pRb and decreased transcriptional
activity of E2F (reviewed by Hocevar and Howe, 1998).
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The well-accepted model of TGF-ß-induced G1 arrest is a Myc-p15-p27-Cdk-pRb
axle (Massagué et al, 2000). TGF-ß treatment rapidly suppresses the expression of the
c-myc oncogene, which results in the induction of p15 in a variety of different cell
types, including lung, thyroid, mammary epithelial cells, and astrocytes (Massagué et
al., 2000). p15 specifically inhibits cyclin D-Cdk4/6 kinases via binding to Cdk
subunits, inactivating the catalytic activity and preventing the assembly of new cyclin
D-Cdk complexes from the latent pools. Association of p15 with Cdk4/6 frees another
Cdk inhibitor, p27, from cyclin D complexes and allows its binding to and inhibition
of cyclin E-Cdk2 activity (Reynisdottir et al., 1995; Reynisdottir and Massagué, 1997;
Sandhu et al., 1997). Thus, by increasing the level of one single Cdk inhibitor, TGF-ß
inhibits both classes of G1 Cdks (Massagué et al., 2000) (Fig. 5).
2.4.2 Regulation of Myc and p15 by TGF-ß
The proto-oncogene c-myc encodes a transcription factor which plays crucial roles
in various cellular processes such as proliferation, loss of differentiation, and
apoptosis (Amati et al., 1998; Levens, 2002; Pelengaris et al., 2002). Myc forms a
dimeric complex with its partner protein, Max, and achieves the function via either
activating or repressing numerous target genes (Kretzner et al., 1992; Amati et al.,
1993).
Expression of c-myc is rapidly reduced by TGF-ß, and this reduction is thought to
be the “core” of TGF-ß-mediated growth inhibition machinery (Chen et al., 2000;
Massagué et al., 2000). The molecular mechanism of regulation of myc and p15 has
been suggested by several groups. In the absence of TGF-ß, Myc and its partner Max
stably interact with Myc-interacting zinc-finger protein (Miz-1, a transcription factor)
on the transcription initiator (Inr) element of p15, and block the transactivation
capability of Miz-1 (Seoane et al., 2001; Staller et al., 2001). Upon TGF-ß treatment,
a subgroup of Smad3 in cytoplasm associating with transcription factors E2F4/5 and
DP1 and corepressor p107 moves into the nucleus together with Smad4, and represses
the expression of c-myc (Chen et al., 2002). As Myc has a short half-life
(approximatly 10 min), this repression results in a rapid loss of Myc protein and
relieves the repression on p15.
However, relief of Myc-mediated repression is insufficient for the induction of
p15, since this induction is not observed in epithelial cells whenever the levels of c-
myc decline, such as with serum deprivation. TGF-ß has been reported to induce the
formation of a Smad complex binding to p15 promoter and to trigger the expression
of p15. Inteference with, or deficiency in, Smad2, Smad3, or Smad4 functions reduces
or abolishes TGF-ß-dependent p15 induction (Feng et al., 2000). Overexpression of
Smad3 in Smad3 null mouse astrocytes fails, however, to increase p15 expression
(Rich et al., 1999), suggesting that both reduction in c-myc and formation of Smad
complex are required for p15 induction in response to TGF-ß.
A model of TGF-ß-mediated induction of p15 has been suggested by Seoane et al.
(2001). Treatment of TGF-ß reduces the expression of Myc, which allows Miz-1 to
associate with the Smad complex, which formed upon TGF-ß addition, on p15
promoter, and to induce the expression of p15 (Seoane et al., 2001). Thus, two
separate TGF-ß-dependent events: relief of Myc repression and Smad-mediated
transactivation, cooperate in controlling p15 activation.
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Fig 5. TGF-ß induces G1 cell cycle arrest. TGF-ß rapidly represses c-myc expression and induces p15
expression. p15 specifically binds to Cdk4/6 and inhibits the formation of the  cyclin D-Cdk4/6
complexes, thus abolishing their kinase activities. The dissociation of D-type cyclin-Cdk complexes
frees p27 and allows it to bind to and inhibit cyclin E-Cdk2. Loss of the activities of both cyclin D and
cyclin E complexes results in hypophosphorylated pRb and G1-phase block (Reynisdottir et al., 1995;
Reynisdottir and Massagué, 1997; Reynisdottir and Massagué, 1997; Sandhu et al., 1997; Massagué et
al., 2000).
2.4.3 Regulation of Cdk inhibitors by TGF-ß
p27 and p15 cooperate in the TGF-ß-mediated cell cycle arrest program. Following
TGF-ß treatment, p15 is induced and binds to Cdk4/6 (Hannon and Beach, 1994),
thereby inhibiting the formation of the Cdk4/6-cyclin D-p27 complex in the nucleus.
This allows p27 to associate with the Cdk2-cyclin E complex in the nucleus,
inhibiting Cdk2 kinase activity (Reynisdottir and Massagué, 1997). By affecting the
distribution of p27 in various complexes, TGF-ß inhibits Cdk2 activity without
increasing p27 synthesis (Reynisdottir et al., 1995; Reynisdottir and Massagué, 1997).
A three-fold increase in Cdk2-bound p27 is sufficient to inhibit all cyclin E-Cdk2
activity, and inactivation of p27 by the adenovirus oncoprotein E1A in mink lung
epithelial cells reverses the growth inhibitory effect of TGF-ß (Mal et al., 1996).
TGF-ß regulates p21 expression transcriptionally. p21 level is induced in
keratinocytes, colon, and ovarian epithelial cells as early as at one hour (Elbendary et
al., 1994; Datto et al., 1995; Li et al., 1995). Pardali et al. (2000) described the
molecular mechanism of regulation of the p21 gene by TGF-ß. Upon TGF-ß
treatment, Smad complexes accumulate in the nucleus and interact directly with the
Sp1 transcription factor in the p21 promoter elements, cooperating with CBP and
p300 to trigger the transcription of p21 (Pardali et al., 2000). In addition, it has been
reported that TGF-ß may activate Ras/MAPK pathways to activate c-Jun, which can
then stimulate the expression of the p21 gene (Kardassis et al., 1999; Kivinen and
Laiho, 1999).
With regard to p57, no evidence exists that TGF-ß can upregulate p57 expression
or enhance its association with Cdk complexes (reviewed by Yue and Muler, 2001).
In osteoblasts, however, TGF-ß can actually inhibit p57 expression and enhance Cdk2
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activity, leading to cell proliferation (Urano et al., 1999).
2.4.4 Regulation of Cdks and cyclins by TGF-ß
In addition to the induction of Cdk inhibitors, TGF-ß also affects protein levels or
phosphorylation of Cdks to inactivate their kinase activities. TGF-ß has been shown
to depress Cdk4 and Cdk6 protein levels, with slower kinetics in certain cells, via
posttranscriptional mechanisms (Ewen et al., 1993; Sandhu et al., 1997; Tsubari et al.,
1999). Constitutive expression of Cdk4 leads to the resistant phenotype to TGF-ß
(Ewen et al., 1993). TGF-ß treatment also prevents the increase in Cdk4 levels when
mitogen-deprived cell cultures are replenished with serum; this effect occurs at the
transcriptional level, and is p53-dependent (Ewan et al., 1995). Cdk2 activity is also
suppressed by TGF-ß action, but its ectopic expression fails to override TGF-ß-
induced G1 block (Ewen et al., 1993). Protein levels of cyclin D and cyclin E appear
not to be regulated by TGF-ß (Ewen et al., 1993; Tsubari et al., 1999).
TGF-ß has been shown to inhibit Cdk2-cyclin E complexes by inhibiting the
activity of CAK (Koff et al., 1993; Russo et al., 1996). TGF-ß-induced redistribution
of p27 to the Cdk2-cyclin E complex occludes the CAK-phosphorylating site and
inhibits the phosphorylation (Koff et al., 1993; Russo et al., 1996). In human HepG2
hepatocellular carcinoma cells, TGF-ß treatment does not affect p21, p27, or p15
levels, but resulted in an inactive Cdk2/cyclin E complex, due to the inhibition of
Thr160 phosphorylation on Cdk2 (Nagahara et al., 1999).
Analysis of p15-defective human cancer cell lines has revealed that the anti-
proliferative effect of TGF-ß is also mediated by inhibiting the expression of the Cdk
tyrosine phosphatase Cdc25A (Iavarone and Massagué, 1997). TGF-ß treatment
increases the level of E2F4-p130 complex, which in turn recruits HDAC to the
Cdc25A promoter and inhibits the expression of Cdc25A (Iavarone and Massagué,
1999). A rapid reduction in Cdc25A expression by TGF-ß is observed, however, only
in one mammary epithelial cell line that lacks the expression of p15 (Reynisdottir and
Massagué, 1997). In keratinocytes and gastric carcinoma cells, the effect of TGF-ß on
Cdc25A occurrs 10 to 15 h after TGF-ß treatment (Reynisdottir et al., 1995; Kang
1999), suggesting that it is a secondary effect.
2.4.5 Abrogation of TGF-ß-induced growth arrest
Interference with the components in the pRb pathway blocks the anti-mitogenic
effect of TGF-ß. Full abrogation of the TGF-ß arrest pathway has been achieved by
blocking pRb function by SV40 large T antigen (Laiho et al., 1990), and also by
expression of Myc (Warner et al., 1999). On the other hand, ectopic expression of
Cdk4, Cdk6, or E2F leads to only a partial release of this arrest (Ewen et al., 1993;
Schwartz et al., 1995). Resistance to TGF-ß-mediated growth arrest has also been
ascribed to many other proteins. For example, oncogenic Ras is able to overcome
TGF-ß-mediated arrest. This effect is related to the ability of Ras to increase cyclin D
level and accelerate p27 degradation, as well as to attenuate TGF-ß signal
transduction (Marshall 1999; Saha et al., 2001). Transient overexpression of Mdm2
does not alter the cells´ sensitivity to TGF-ß-mediated growth arrest (Blain and
Massagué, 2000), whereas chronic Mdm2 overexpression may eventually select for
cells resistant to TGF-ß (Sun et al., 1998).
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3 Proteasome-dependent degradation and TGF-ß function
3.1 Ubiquitin-proteasome system and protein degradation
The ubiquitin-proteasome degradation system is responsible for the nonlysosomal
proteolysis of short-lived proteins in eukaryotic cells and is involved in the removal of
nonfunctional proteins and in regulation of the abundance of key proteins. This
system has a broad range of substrates and functions in many cellular processes
including cell cycle progression, apoptosis, immune response, development,
transcriptional regulation, and signal transduction (reviewed by Ciechanover, 1998).
Because of its important roles in cellular life, the aberrations in this pathway have
been related to the pathogenesis of both acquired and inherited human diseases, such
as Parkinson disease, von Hippel Lindau syndrome, and cervical cancer (Vu and
Sakamoto, 2000).
3.1.1 The structure of 26S proteasome
The ATP-powered 26S proteasome is a large (1500-2000 kDa) multi-subunit
complex present in both nucleus and cytoplasm (Machiels et al., 1995). This “protein-
destroying machine” is composed of two distinct sub-complexes: a 20S proteolytic
cylinder flanked by 19S regulatory caps. The 20S proteolytic core was independently
discovered by different groups working in different fields and hence has been given
21 different names (Arrigo et al., 1988; Brown et al., 1991). The name “proteasome”
is now generally accepted, referring to its proteolytic and particulate nature (Arrigo et
al., 1988; reviewed by Gerards et al., 1998). The 20S proteasome is a barrel-like
particle formed by the axial stacking of four rings, made up of two outer a-rings and
two ß-rings, being associated in the order αßßα (Tanaka et al., 1988; Grziwa et al.,
1991; Zwickl et al., 1992; Lowe et al., 1995). The proteolytic sites reside in the ß-ring
element and are defined as trypsin-like, chymotrypsin-like, and post-
glutamylpeptidylhydrolytic activities (reviewed by Schwartz and Ciechanover, 1999).
The 19S particle can be further subdivided into two assemblages: the “base” and the
”lid”. The base contains six “AAA” ATPases which bind to the ends of the 20S
cylinder, rendering proteolysis ATP dependent. The lid includes eight Rpn proteins
assembled together and bound to the base, recruiting substrates upon the prior
synthesis of a multiubiquitin chain on a substrate protein (Glickman et al., 1998).
3.1.2 Ubiquitination
To be targeted to the proteasome, the protein substrates must be labeled with a
multiubiquitin chain (with one clear exception – ornithine decarboxylase (ODC), and
one possible exception – p21 Cdk inhibitor, which is degraded by the proteasome in a
ubiquitin-independent manner) (Murakami et al., 2000; Sheaff et al., 2000). Ubiquitin
is a 76 amino-acid globular protein that is highly conserved throughout eukaryotes,
with only three amino-acid changes from yeast to human. Ubiquitination (or
ubiquitylation) is a multistep process that begins with the activation of ubiquitin by
the E1 ubiquitin-activating enzyme. Activated ubiquitin is transferred from E1 to a
ubiquitin-conjugating enzyme (E2), which then transfers the ubiquitin to the substrate
either by itself, or in cooperation with a ubiquitin ligase (E3). The large number of E2
and E3 enzymes enable the elaboration of numerous ubiquitination pathways and
define the substrate specificity. Once the protein is labeled by a certain type of the
multiubiquitin chain it can be recognized and degraded by the proteasome, generating
oligopeptides and recyclable ubiquitins (reviewed by Vu and Sakamoto, 2000;
REVIEW OF THE LITERATURE
29
Weissman, 2001; Yeh et al., 2001a, b) (Fig. 6).
Besides targeting protein substrates for proteasome degradation, ubiquitination also
has other cellular functions depending on the type of ubiquitination. For instance,
monoubiquitination is involved in endocytosis, protein sorting, and subnuclear
trafficking (reviewed by Hicke, 2001). Different multiubiquitination chains target
protein substrates to different pathways such as proteasome-mediated degradation,
DNA repair or endocytosis (Pickart, 2001; Weissman, 2001).
Ubiquitination can be reversed by deubiquitination, which offers another regulation
level. Deubiquitination is performed by deubiquitination enzymes (DUBs) that
specifically cleave ubiquitin from ubiquitin precursors, ubiquitin-protein conjugates,
and ubiquitin adducts (Wilkinson, 2000).
Fig. 6. The ubiquitin-proteasome pathway. Ubiquitin (U) is activated by E1 ubiquitin-activating
enzyme in an ATP-dependent manner. Activated ubiquitin afterwards is transferred from the E1
enzyme to the E2 ubiquitin-conjugating enzyme, which then transfers the ubiquitin to the substrate
either by itself or in cooperation with E3 ubiquitin ligase. The protein target labeled by polyubiquitin
chain can be recognized by the proteasome (Pro), in which the protein target is degraded, resulting in
recyclable ubiquitins and peptides (Verma and Deshaies, 2000; Vu and Sakamoto, 2000; Weissman,
2001; Yeh et al., 2001a, b. The figure is modified from Pickart, 2001 and Sakamoto, 2002).
3.2 Proteasome-mediated protein degradation and TGF-ß signaling
TGF-ß signaling relies on the receptor-Smad transduction pathway. The
specificity, diversity, intensity, and timing of TGF-ß signaling are tightly controlled
by activation and inactivation of signal transduction components. One of the effective
regulation mechanisms is the ubiquitin-proteasome-dependent degradation of key
transducer proteins (Table 2).
The involvement of proteasome degradation in the TGF-ß signal transduction
pathway was first reported by the Massagué and Weinberg groups  (Lo and Massagué,
1999; Sun et al., 1999b). TGF-ß receptor-mediated activation leads to
multiubiquitination and subsequent degradation of Smad2 by the proteasome. If the
degradation is blocked, the phospho-Smad2 remains in the nucleus in an active state.
ATP
U
Pro
+ Peptide
E3
E2
E2
E1
E1
target
target target
U
U
U
U
U
U
U
U
AMP
REVIEW OF THE LITERATURE
30
The ubiquitination is probably a result of Smad accumulation in the nucleus but is not
a result of phosphorylation. Smad2 in the basal state appears to turnover by a different
mechanism (Lo and Massagué, 1999). Afterwards, Smurf2 is identified as the E3
ubiquitin ligase for proteasome-dependent degradation of Smad2 (Lin et al., 2000).
Another R-Smad, Smad3, is also degraded via the proteasome system in response to
TGF-ß treatment, mediated by ROC1 and associated proteins (Fukuchi et al., 2001).
In addition, Smad7, an inhibitor of TGF-ß signaling, can recruit Smurf2 to the TGF-ß
receptor type I and target it for degradation (Kavsak et al., 2000).
Not only the transducers of TGF-ß signaling (receptors and R-Smads) are targeted
to ubiquitin-proteasome degradation, but the inhibitor SnoN is also a substrate for
proteasome degradation (Sun et al., 1999b; Bonni et al., 2001; Stroschein et al., 2001)
(See Review of the Literature 1.5.3). Accordingly, the proteasome degradation system
is involved in the proteolysis of both positive and negative regulators of TGF-ß
signaling.
Interestingly, the disruption of proper degradation of Smads has been observed in
human cancers. Xu and Attisano (2000) identified a missense mutation at a conserved
arginine residue in both Smad2 and Smad4 in colorectal and pancreatic cancers. This
mutation does not prevent the receptor-mediated phosphorylation of Smad2, the
formation of Smad2/Smad4 complexes, as well as the nuclear translocation of Smads,
but increases the turnover rate of Smad proteins via the proteasome pathway. The
mutant Smads are degraded rapidly in comparison with the wild type counterparts via
the ubiquitin-proteasome pathway, suggesting that some tumors accelerate
degradation of TGF-ß signaling components, thus avoiding TGF-ß-mediated growth
inhibition (Xu and Attisano, 2000).
Table 2. Ubiquitin ligases for proteasome-mediated degradation of TGF-ß signaling
components.
TGF-ß signaling component    Ubiquitin ligase              Reference
Receptor type I Smurf1, Smurf2 Kavsak et al., 2000; 
Ebisawa et al., 2001
Smad2 Smurf2 Feng et al., 2000
Smad3 ROC1-SCFFbw1a Fukuchi et al., 2001
Smad7 Smurf1, Smurf2 Kavsak et al., 2000;
Ebisawa et al., 2001
SnoN Smurf2, APC Stroschein et al., 2001;
Wrana et al., 2001
 
3.3 Proteasome-mediated protein degradation and cell cycle progression
Proper cell cycle progression relies on the coordinated activation and inactivation
of cell cycle regulators. Proteasome-mediated degradation is involved in the
regulation of the abundance of these cell cycle machinery proteins and contributes to
their periodic levels during the cell cycle. Cyclin D1 is targeted to proteasome
degradation after phosphorylation on Thr286 by glycogen synthase kinase-3ß (GSK-
3ß) (Diehl et al., 1997; Diehl et al., 1998). Tumor necrosis factor-α (TNF-α) is also
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able to induce proteasome-dependent degradation of cyclin D1 and arrest the cell
growth (Hu et al., 2002). p27 was found to be degraded by the ubiquitin-proteasome
pathway, mediated by the ubiquitin-conjugating enzymes Ubc2 and Ubc3 and E3
ligase Skp2 (Pagano et al., 1995). In addition, cyclin E is also degraded by the
proteasome in non-Cdk2-bound form, and this degradation is also regulated by Cdk2
catalytic activity (Clurman et al., 1996). In addition, p57, p21, p19, and E2F are also
reported to be degraded via proteasome (Machiels et al., 1997; Wang et al., 1998;
Kumeda et al., 1999). Furthermore, proteasome activity is also suggested to be
required for the progression of the S-phase. Treatment with proteasome inhibitors
block the later replicating origins and inhibit the cell cycle in the S-phase (Yew and
Kirschner, 1997; Hua and Newport, 1998; Yamaguchi et al., 2000; reviewed by Yew,
2001).
3.4 Proteasome inhibitors used in research and anti-cancer therapy
The 26S proteasome is involved in many important cellular processes, and hence
has become a major subject for research. One of the most useful tools for exploring its
function is to utilize the specific inhibitors. Several classes of proteasome inhibitors
are currently used in the research field, such as peptide aldehydes (such as MG132
and LLnL), streptomyces metabolite (lactacystin), dipeptidyl boronic acids (PS-341),
and other material (eponomycin) (reviewed by Almond and Cohen, 2002). The
inhibitors commonly used are MG132 and lactacystin. MG132 reversibly and potently
inhibits the chymotrypsin-like activity of the proteasome (Rock et al., 1994; Lee and
Goldberg, 1998) but also affects the activities of calpain I and cathepsin B (Rock et
al., 1994). Lactacystin is isolated from actinomycetes and found to block proliferation
of several cell types (Omura et al., 1991). It shows high specificity for the proteasome
but also inhibits cathepsin A (Fenteany et al., 1995; Dick et al., 1996).
The strong capability of proteasome inhibitors to induce apoptosis in vitro (Imajoh-
Ohmi et al., 1995; Shinohara et al., 1996; Drexler, 1997; Almond, 2001) has attracted
attention to their potential use in cancer chemotherapy. Some of the proteasome
inhibitors exert anti-tumor activity in vivo, including those tumors resistant to
conventional chemotherapeutic agents. These inhibitors may also prevent
angiogenesis and metastasis and further increase the sensitivity of cancer cells to
apoptosis (reviewed by Almond and Cohen, 2002). The first proteasome inhibitor
entering human trials is PS-341, which has shown anti-tumor activity in a variety of
tumors including myeloma, prostate cancer, pancreatic cancer, and colon cancer, in a
reversible and dose-dependent manner (reviewed in Adams, 2001). Phase I trials
suggest that PS-341 is well tolerated (Orlowski et al., 2002), and further human trials
are ongoing.
4 TGF-ß and breast cancer
4.1 Functions of TGF-ß in normal mammary gland
TGF-ß potently inhibits the growth of epithelial cells in lobules and ducts of the
normal mammary gland, and thereby controls its development and function
(Silberstein and Daniel, 1987; Daniel and Robinson, 1992; Barcellos-Hoff and Ewan,
2000). Studies on the gain or loss of function in animal models suggest that
endogenous TGF-ß has both direct and indirect effects on morphogenesis and
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function of the mammary epithelium. TGF-ß acts directly on the mammary epithelium
to prevent precocious alveolar development and milk protein production in virgin
mice. Acting indirectly, via the stroma, TGF-ß limits ductal branching and maintains
correct ductal spacing (Wakefield et al., 2000). TGF-ß transgenic mice show
decreased ductal development in young animals (Pierce et al., 1993, 1995) and
inability to lactate due to decreased maintenance of lobuloalveolar structures (Jhappan
et al., 1993; Kordon et al., 1995).
4.2 Functions of TGF-ß in breast cancer
TGF-ß has been suggested to play a tumor suppressive function in the mammary
gland (Reiss and Barcellos-Hoff, 1997). In a transgenic mouse model, in which a
simian TGF-ß mutant producing a constitutively active product under the control of
the mouse mammary tumor virus (MMTV) promoter is expressed, the tumorigenesis
in the mammary gland induced by chemical carcinogens or oncogenes is inhibited
(Pierce et al., 1993, 1995). In mice carrying the dominant negative mutant TGF-ß
type II receptor, an increase in spontaneous tumorigenesis in aged animals is evident
(Gorska et al., 1998), and the animals are hypersensitive to carcinogens (Bottinger et
al., 1997). Cells isolated from human breast cancers are usually less sensitive to TGF-
ß-induced growth arrest compared with normal human mammary epithelial cells
(Fynan and Reiss, 1993; Reiss and Barcellos-Hoff, 1997).
In breast cancer, although TGF-ß can be tumor suppressive, increasing evidence
indicates that TGF-ß also has pro-oncogenic activities: advanced human breast tumors
overexpress TGF-ß (Koli and Arteaga, 1996), and TGF-ß secreted by tumor cells
and/or stromal cells within the peritumoral microenviroment contribute to tumor
maintenance and progression, in part by enhancing the motility and invasiveness of
tumor cells (Welch et al., 1990; Oft et al., 1996; Yin et al., 1999). This tumor-
promoting effect can be either direct, or indirect via the stroma. Direct effects include
promotion of the epithelial-mesenchymal transition and invasiveness of the tumor
cells themselves, and an increase in production of parathyroid hormone-related
peptide (PTHrP), which stimulates osteolytic bone metastasis in breast cancer
(Juppner et al., 1991; Yin et al., 1998; Dumont and Arteaga, 2000). Indirect effects
include induction of angiogenesis and suppression of the immune surveillance system
(Wakefield et al., 2000). In a murine model of bone metastases, expression of a
dominant negative mutant of the TGF-ß type II receptor in the human breast cancer
cell line MDA-MB-231 has resulted in less bone destruction, fewer tumors with
osteoclasts, and prolonged survival. Reversal of the dominant-negative signaling
blockade by expression of a constitutively active TGF-ß type I receptor in breast
cancer cells increases tumor production of PTHrP, which in turn enhances the
osteolytic bone metastasis, and leads to reduced survival (Yin et al., 1999).
Accordingly, much evidence suggests that breast cancers selectively read the TGF-
ß signal. The anti-proliferative signal is ignored, whereas the tumor-promoting signal
goes through. To date there is no solid evidence how this selectiveness is achieved.
4.3 Mechanisms of loss of anti-proliferative response to TGF-ß in breast cancer
Defects in TGF-ß signal transduction pathways or downstream events affecting cell
cycle regulation have been reported in human tumors (reviewed by Kretzschmar,
2000). In addition, TGF-ß function also interacts with other mitogenic or anti-
mitogenic signals. Any disruptions at these steps may attenuate the TGF-ß growth
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arrest effect and lead to malignant growth.
4.3.1 Alteration of TGF-ß signaling components in breast cancer
The anti-proliferative effect of TGF-ß is mediated by the receptor-Smad signal
pathway. Loss of growth inhibitory responses to TGF-ß in the cancer cell may result
from inactivating mutations or aberrant expression of TGF-ß signaling components.
Though this is the case in many cancers such as gastrointestinal and lung cancers, in
breast cancer, the aberrations of TGF-ß signaling components are rarely reported
(reviewed by Wakefield et al., 2000). Furthermore, breast cancer cells that are no
longer growth inhibited by TGF-ß still display some responses to TGF-ß-induced
gene expression typical of nontumorigenic mammary epithelial cells  (see a genome-
wide study by Chen et al., 2001). In fact, breast cancer cells appear to derive an
advantage maintaining the TGF-ß signaling engine while losing anti-proliferative
responses (Yin et al., 1999). This is consistent with the dual functions of TGF-ß in
breast cancer. Alternative mechanisms to abolish growth inhibitory responses to TGF-
ß must therefore be involved in most breast carcinomas (Wakefield et al., 2000).
4.3.2 Alteration of cell cycle machinery in breast cancer
The anti-proliferative response of tumor cells to TGF-ß can also be affected by
dysregulation of the cell cycle regulators that function downstream to the receptor-
Smad pathway. Such alterations are frequently found in human breast tumors and
include lost repression of Myc, increased expression of cyclin D1, cyclin E, or Mdm2,
decreased expression of p16 or p27, and mutations in pRb or p53 (reviewed by
Donovan and Slingerland, 2000).
Myc is repressed by TGF-ß, and artificial averting of Myc repression blocks TGF-
ß-induced growth inhibition (Warner et al., 1999; Claassen and Hann, 2000). A
genome-wide analysis of rapid TGF-ß gene responses in MCF-10A human mammary
epithelial cells and MDA-MB-231 breast cancer cells shows that Myc repression is
selectively lost in the cancer cell line (Chen et al., 2001), suggesting a possible target
of tumorigenesis in breast cancer.
Overexpression and/or amplification of the cyclin D1 gene is seen in up to 40% of
breast cancers (Lammie et al., 1991; Buckley et al., 1993). Increased cyclin E protein
has also been observed in breast cancers (Porter et al., 1997). Amplification of the
Cdk4 gene occurs in primary breast cancers, and increased Cdk4 protein may exceed
the level of p15 and prevent Cip/Kip inhibitors from inhibiting Cdk2-cyclin E
complex, thus accelerating the cell cycle progression (An et al., 1999). Although
mutations in p27 are rare (Kawamata et al., 1995; Pietenpol et al., 1995), accelerated
proteolysis causes a reduction in p27 protein in many cancers, including breast, and
may contribute to TGF-ß resistance (Porter et al., 1997; Tan et al., 1997; Slingerland
and Pagano, 2000). Less often, primary tumors may exhibit strong cytoplasmic p27
expression associated with poor prognosis (Orend et al., 1998; reviewed by Blain and
Massagué, 2002). Loss of p21 has also been observed in advanced breast cancers in
association with poor patient prognosis (Jiang et al., 1997; Tsihlias et al., 1998).
4.3.3 Crosstalk with other mitogenic signals in breast cancer
The loss of response to TGF-ß-induced growth inhibition coincides with the
presence of a hyperactive Ras pathway in some breast cancers. Transformation of
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human mammary epithelial cell MCF-10A with Ras oncogene selectively inhibits c-
myc repression by TGF-ß and abolishes the cell cycle arrest (Chen et al., 2001). In
addition, Ras can also interfere with TGF-ß functions at different levels; for example,
by upregulating the activities of G1-phase cyclin-dependent kinases (Takuwa N and
Takuwa Y, 2001).
Although oncogenic Ras mutations in breast cancers are not common (found in
about 5% of all cases) (Rochlitz et al., 1989), about one-third breast carcinomas
amplify or overexpress ERBB2 receptor tyrosine kinase (Press et al., 1997; Dillon et
al., 1998). Furthermore, overexpression of the related EGF receptor is also observed
in a significant number of cases (Rajkumar and Gullick, 1994). Stimulation of the
Ras/MAP-kinase pathway is a major component of the proliferative signals of these
receptors. Therefore, oncogenic avivation of Ras effector pathways may contribute to
the loss of antiproliferative effect of TGF-ß.
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AIMS OF THE STUDY
This study is undertaken to understand the molecular mechanisms of TGF-ß-
induced G1 cell cycle arrest and its disruption in tumorigenesis at both the signal
transduction level and the downstream cell cycle machinery level. TGF-ß has been
shown to affect the levels of Cdks and their inhibitors, though the relative contribution
of the downregulation of the Cdks, especially of Cdk6, is not fully understood.
Several cell cycle and TGF-ß signaling components undergo proteasome degradation.
However, it is unclear how TGF-ß signal transduction and its effect on the cell cycle
arrest are affected by the proteasome activity. Furthermore, loss of growth regulatory
properties of TGF-ß through alterations in its signaling transducers have been
suggested to be the underlaying causes of some cancers. However, breast tumors,
despite a loss of TGF-ß growth inhibitory response, do not show much alteration in
TGF-ß signal transducers. We therefore want to address the following questions:
1)  What is the significance of Cdk6 downregulation in TGF-ß-mediated G1-cell
cycle arrest?
2) How is TGF-ß signal transduction and TGF-ß-induced G1-phase arrest affected by
the proteasome degradation system?
3)  What is the function of SnoN, a TGF-ß signaling inhibitor, in breast cancer
tumorigenesis and tumor progression?
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The materials and methods used in this study are liseted in the tables below.
1. Cell lines
  Cell line                               Description                                       Source                Used in
Mv1Lu mink lung epithelial cell ATCC I-III
Cdk6-9 Mv1Lu cells overexpressing Generated in I I
human Cdk6
Cdk6-DN-3 Mv1Lu cells overexpressing Generated in I I
                               dominant negative Cdk6
2. Tissues
   Tissue                                     Description                                     Source                Used in
Human breast breast cancer tissues from FinProg Breast IV
cancer tissue patients of nationwide Finnish Cancer Database
microarray Cancer Registry
normal tissue tissue microarray containing 21 Ambion Inc. IV
microarray types of normal human tissues
reduction mammoplasty sections containing normal breast Dept. of Pathology, IV
speciments tissues University of Helsinki
3. Plasmids
Plasmid                          Description                                          Source                      Used in
pP15 human p15 in pSG5 Tsubari et al., 1997 I
pCdk2 human Cdk2 cDNA in pRc/CMV Dr. Tomi Mäkelä, I
University of Helsinki
pCdk4 human Cdk4 cDNA in pSG5 Dr. Tomi Mäkelä I
pCdk6 human Cdk6 cDNA in pRc/CMV Dr. Ed Harlow, I
Massachusetts General
Hospital Cancer Center
pCdk6-DN human dominant negative Dr. Ed Harlow I
Cdk6 in pRc/CMV
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4. Growth factors, chemicals, and antibodies
Growth factor/chemical/antibody            Source                                                       Used in
TGF-ß1 human platelets I-III
MG132 Affinity Research Products Ltd II, III
lactacystin Calbiochem III
α-5-BrdU (RPN202) Amersham Life Sciences I, III
α-Cdk2 (M2) Santa Cruz Biotechnology I, III
α-Cdk4 (C-22) Santa Cruz Biotechnology I, III
α-Cdk4 (Ab-1) Neomarkers I
α-Cdk6 (C-21) Santa Cruz Biotechnology I, III
α-cyclin D1(H-295) Santa Cruz Biotechnology I
α-cyclin D2 (C-17) Santa Cruz Biotechnology I, III
α-cyclin E (M-20) Santa Cruz Biotechnology I
α-cyclin E (06-459) Upstate Biotechnology I, III
α-p15 (C-20) Santa Cruz Biotechnology I
α-p27 (C-19) Santa Cruz Biotechnology I, III
α-phospho-Smad2 Dr. Peter ten Dijke, the II
Netherlands Cancer Institute, and
Dr. Carl-Henrik Heldin, Ludwig
Institute for Cancer Research,
Uppsala Branch
α-pRb (C-15) Santa Cruz Biotechnology I, III
α-Smad2/3 (610843) BD Transduction Laboratories II
α-SnoN (H-317) Santa Cruz Biotechnology II
α-SnoN (K-20) Santa Cruz Biotechnology IV
5. Methods
Technique                                                                                  Used and described in
5-BrdU incorporation assay I, III
cDNA cloning I
Flow cytometry III
Immunofluorescence staining I-III
Immunohistochemical staining IV
Immunoprecipitation I, III
Kinase assay I, III
Northern blot analysis II
Statistical analysis by Chi-square (χ2)-test IV
Statistical analysis by Kaplan-Meier test IV
Transfection by calcium phosphate precipitation methods I
Tissue microarray assay IV
Western blot analysis I-III
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RESULTS AND DISCUSSION
1 Downregulation of Cdk6 kinase activity is crucial for TGF-ß-
induced growth inhibition (I)
We have previously reported that in Mv1Lu mink epithelial cells TGF-ß reduced
the level of Cdk6 by inhibiting its synthesis and increasing its turnover, and that
hepatocyte growth factor (HGF) abolished the anti-proliferative effect of TGF-ß by
restoring Cdk6 activity (Tsubari et al., 1999). On the other hand, some tumor cells
displaying the TGF-ß-resistant phenotype have elevated levels of Cdk6 (Costello et
al., 1997; Chilosi et al., 1998; Corcoran et al., 1999). These findings suggest that
downregulation of Cdk6 protein level, and thus its kinase activity, plays an important
role in TGF-ß-mediated growth inhibition, and an increase in Cdk6 level may
contribute to malignant growth in tumor cells. To understand the molecular details of
the function of Cdk6 in the TGF-ß growth-inhibition program, we generated stable
clones overexpressing wild type Cdk6 or dominant negative (DN) Cdk6 in Mv1Lu
and analyzed the G1/S-phase progression regulated by TGF-ß.
The cell cycle distributions of the Cdk6-overexpressing cells (Cdk6-9, the wild
type Cdk6-overexpressing clone; Cdk6-DN-3, the dominant negative Cdk6-
overexpressing clone) were analyzed. No significant changes were evident in the cell
cycle compared with the parental cells, except that Cdk6-9 displayed a slightly
increased S-phase population. Surprisingly, even though the dominant negative Cdk
protein harbors a mutation in the ATP-binding site, and its overexpression should
abolish the activity of endogenous Cdk and thus prevent the S-phase entry, we did not
see obvious changes in cell cycle distribution in the Cdk6-DN-3 clone. This is
concordant with a previous report that in contrast to ectopic expression of Cdk2-DN
or Cdk3-DN which blocks the cell cycle progression, Cdk6-DN does not affect cell
cycle distribution (van den Heuvel and Harlow, 1993). One possible explanation is
that loss of Cdk6 activity is compensated by the endogenous Cdk4.
1.1 TGF-ß growth inhibition is attenuated by overexpression of wild type Cdk6
To address the regulation of Cdk6 by TGF-ß, time- and dose-dependency studies
were carried out in Mv1Lu cells. As shown in Fig. 1 (I), TGF-ß reduced Cdk6 levels
in a time- and dose-dependent manner. Furthermore, this reduction was in line with
TGF-ß-induced withdrawal of cells from the cycle. Though TGF-ß dramatically
reduced the Cdk6 level in mink cells, this regulation was lost in Cdk6-overexpressing
clones (I, Fig. 3). Additionally, TGF-ß-induced blockade of DNA replication was
attenuated in the wild type Cdk6-overexpressing cells (Cdk6-9), but not in DN-Cdk6-
overexpressing cells (Cdk6-DN-3, I, Fig. 2). However, the overriding of TGF-ß-
growth arrest by wild type Cdk6 was only partial (I, Fig. 2 and 3). The analysis of two
additional Cdk6 and two Cdk6-DN clones gave similar results, hence excluding the
clonal variations.
Because ectopic expression of Cdk4 has previously been shown to abrogate TGF-ß
growth arrest (Ewen et al., 1993), we addressed whether co-expression of both Cdk6
and Cdk4 would fully overcome the TGF-ß growth inhibition. Clones co-expressing
Cdk6 and Cdk4 were established. Inhibition of DNA replication by TGF-ß was
similar in these double-transfectants to that in Cdk6 clones (data not shown). Full
abolition of TGF-ß arrest has been achieved in Mv1Lu cells by expression of Myc
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(Warner et al., 1999) or by expression of SV40 T antigen (Laiho et al., 1990). On the
other hand, ectopic expression of Cdk4, Cdk6, or E2F leads to only a partial release of
the arrest (Ewen et al., 1993; Schwartz et al., 1995; I). Here, we found that co-
expression of Cdk4 and Cdk6 failed to fully overcome TGF-ß-induced growth arrest.
This result suggests that Cdk4 and Cdk6 may have overlapping functions in the same
pathway in TGF-ß-induced growth inhibition. Restoration of the activities of both
Cdk4 and Cdk6 was not able to fully circumvent the arrest, and other factor, probably
cyclin E-Cdk2 activity, was also required to overcome the TGF-ß arrest.
1.2 Cyclin D-related kinase activity is maintained in wild type Cdk6-
overexpressing cells treated with TGF-ß
To address how TGF-ß regulatory events are affected in Cdk6 clones, we analyzed
in detail the regulation of various Cdks, cyclins, and Cdk inhibitors. The levels of
cyclin D1, -D2, and p27 showed no changes in response to TGF-ß in the parental cells
and in Cdk6 clones (I, Fig. 3), consistent with previous data (Reynisdottir et al., 1995;
Reynisdottir and Massagué, 1997; Tsubari et al., 1999). Cdk4 protein level was
reduced in all of the cell lines, though less efficiently in Cdk6 clones (I, Fig. 3).
Interestingly, though Cdk6-9 cells resist TGF-ß-growth inhibition, p15, a Cdk
inhibitor thought to be an important factor of TGF-ß-induced G1 arrest (Lin et al.,
2001), was still induced in this cell line as well as in the parental cell line and the
Cdk6-DN-3 clone. This implied that ectopically expressed Cdk6 affected TGF-ß
function at the cell cycle machinery level rather than in the upstream signaling
pathway. Analysis of pRb phosphorylation status (via western blot) showed that most
of the pRb remained in its slowly migrating phosphorylated form in the Cdk6-9 cells
(I, Fig. 3) consistent with the resistance to TGF-ß arrest.
The proper function of Cdk4/6 requires the formation of a trimer complex of cyclin
D-Cdk4/6-p27. In the parental mink cells, TGF-ß-induced p15 associated with Cdk6
and dissociated the cyclin D2-Cdk6-p27 complex (I, Fig. 4). Interestingly, in the
absence of TGF-ß, the Cdk6 clones showed elevated levels of p15 in association with
Cdk6 proteins than did the parental mink cells (I, Fig. 4). This indicates that in
physiological conditions, there is more p15 protein at baselevel than Cdk6 protein,
and that the increased Cdk6 protein is able to sequester more p15 protein. TGF-ß
treatment stimulated the expression of p15 and further enhanced the association of
p15 with Cdk6 in both clones (I, Fig. 4). In these clones, however, we observed no
apparent decrease in Cdk6-associated p27 upon TGF-ß treatment. This reflected the
excess of Cdk6 presented in the cells, which then saturated p15 proteins and
prevented p27 from shifting from Cdk6 complex to Cdk2 complex (I, Fig. 4).
Although there were increased levels of Cdk6 bound to either cyclin D2 or p27 in the
Cdk6 overexpressing clones, p27 association with cyclin D2 was not increased (I, Fig.
4), implying that in these clones the level of cyclin D2-Cdk6-p27 trimeric complex
was not increased.
Analysis of the Cdk4-cyclin D2-p27 complex showed that Cdk6 clones had less
cyclin D2- or p27-bound Cdk4 than did the parental mink cells (I, Fig. 4), probably
due to the high level of Cdk6, which sequestered both cyclin D2 and p27 from the
Cdk4 complex. TGF-ß destroyed Cdk4 complex in the parental mink cells as well as
in the Cdk6 clones but to a lesser extent (I, Fig. 4).
Examination of the kinase activity showed that the cyclin D2-associated kinase
activity is comparable in the wild type Cdk6 clone to that in the parental cell (I, Fig.
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4), which is concordant with the finding that there was no increase in the level of
cyclin D2-Cdk6-p27 trimeric complex, indicating that the increase in Cdk6 alone does
not promote kinase activity and that a rate-limiting step exists, which is conferred by
such components as cyclin D or p27. TGF-ß treatment reduced cyclin D2-associated
kinase activity towards pRb in Mv1Lu cells (I, Fig. 4). The wild type Cdk6
successfully prevented the downregulation of cyclin D2-associated activity by TGF-ß,
whereas the Cdk6-DN failed to do so (I, Fig. 4), suggesting that the intact kinase
activity of Cdk6 is required for protecting cyclin D-associated kinase activity.
1.3 Cdk2-associated kinase activity is partially maintained in TGF-ß-treated wild
type Cdk6-overexpressing cells
Next we examined the regulation of Cdk2-cyclin E complex by TGF-ß. In parental
mink cells, TGF-ß induced an increase in p27 associated with Cdk2-cyclin E (I, Fig.
5A), leading to the loss of its kinase activity (I, Fig. 5B) (see also Reynisdottir et al.,
1995; Reynisdottir and Massagué 1997). In Cdk6 clones, the fraction of p27
complexed with either Cdk2 or cyclin E was also increased, but to a lesser extent (I,
Fig. 5A), resulting in the partially maintained cyclin E-Cdk2 kinase activity (I, Fig.
5B). Since the p27 bound to complexes with Cdk6 in the ectopic Cdk6 clones was not
noticeably reduced by TGF-ß, p27 relocalized to the Cdk2 complex appears to be
derived from the Cdk4 complex. Possibly because a fraction of cyclin E-associated
kinase activity is still lost, the wild type Cdk6 clone cannot fully escape from TGF-ß
growth inhibition.
1.4 Cdk6 and Cdk4 but not Cdk2 drive re-entry of TGF-ß-arrested Mv1Lu cells
into the S-phase
Mink cells continuously expressing wild type Cdk6 show resistance to TGF-ß-
induced G1 cell cycle arrest. We further wanted to test whether Cdk6, or other Cdks,
in comparison, can force cell cycle re-entry in TGF-ß-arrested cells. We transiently
expressed Cdk6, Cdk4, Cdk2, or Cdk6-DN in TGF-ß-inhibited cells and analyzed
their effects on DNA replication by 5-BrdU incorporation assay. The results showed
that Cdk4 and Cdk6 were able to drive re-entry of the arrested cells into the S-phase,
whereas Cdk2 and Cdk6-DN failed to do so (I, Fig. 6), indicating that Cdk2 requires
collaboration with Cdk4/6 to override TGF-ß-induced growth inhibition.
In this study, we showed that TGF-ß downregulated Cdk6 level and that transient
and stable expression of Cdk6 overrode TGF-ß-mediated arrest. Ectopically expressed
Cdk6 sequestered TGF-ß-induced p15, and thus maintained p27 in the Cdk4/6-cyclin
D complex and prevented its complete shift to the Cdk2-cyclin E complex. This led to
the presence of active cyclin D complexes and a partially active cyclin E complex,
and resulted in the failure of TGF-ß to fully arrest cell growth. In contrast, Cdk6-DN
failed to affect TGF-ß-induced growth inhibition, suggesting that not only the protein
level, but also an intact kinase activity of Cdk6 is required for overriding TGF-ß
effect. An increase in the Cdk6 activity has little effect on cell cycle distribution itself,
since cyclin D and p27 may act as the rate-limiting factors. On the other hand,
increased Cdk6 is able to help cells to escape from growth inhibition carried out by
some factors, in this case TGF-ß, thus triggering the malignant growth. These results
indicate that downregulation of Cdk6 kinase activity is required for TGF-ß-exerted
G1 cell cycle arrest and that tumor cells may escape from TGF-ß regulation by
increasing Cdk6 kinase activity.
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Cdk4, another D-type cyclin-dependent kinase, has also been reported to be
reduced by TGF-ß in Mv1Lu cells, and constitutive expression of Cdk4 leads to TGF-
ß resistance (Ewen et al., 1993). Interestingly, overexpression of Cdk4 or Cdk6
attenuates TGF-ß growth arrest only partially, and co-expression of these Cdks fails to
fully overcome the growth inhibition. Cdk4 and Cdk6 co-exist in most tissues,
whereas their relative abundance differs among different tissues, and the activation of
Cdk4 and Cdk6 in response to mitogenic stimuli is cell type-specific (Orteaga, 2002),
suggesting that Cdk4 and Cdk6 have overlapping but also distinct functions. The
activity of Cdk2, another G1/S-phase Cdk, is also reduced by TGF-ß, but ectopic
expression of Cdk2 is not able to override TGF-ß-induced G1 arrest (Ewen et al.,
1993). Since Cdk2 functions downstream to Cdk4/6, it is plausible that without
Cdk4/6, the recovery of Cdk2 activity alone cannot restore the full G1/S-Cdk
activities required for the S-phase entry.
2 TGF-ß signaling is regulated by a proteasomal inhibitor in a gene-
specific manner (II)
Several key components of TGF-ß signal transduction are degraded through the
ubiquitin-proteasome system. Smad2 and Smad3 are degraded by the proteasome via
Smurf2 and ROC1 E3 ligases, respectively (Lin et al., 2000; Fukuchi et al., 2001).
Smad7 recruits Smurf2 to TGF-ß receptor and induces the degradation, and Smad7
itself is also a substrate for proteasome-dependent degradation (Kavask et al., 2000).
SnoN, a newly identified repressor of TGF-ß signaling, is degraded via the ubiquitin-
proteasome pathway, which is mediated by the anaphase-promoting complex (APC)
or by Smurf2 E3 ligases (Bonni et al., 2001; Stroschein et al., 2001; Wan et al.,
2001). Accordingly, TGF-ß signaling is controlled by the proteasome both positively
and negatively: degradation of SnoN maintains the signal, but degradation of
phospho-Smad2/3 turns it off. Regulation of these two events ensures that TGF-ß
signaling to continue or to stop at appropriate times corresponding to the
environmental cues of the cells. By utilizing an inhibitor of proteasome, we analyzed
the function of the proteasome system in the regulation of TGF-ß signaling
components and the expression of TGF-ß-responsive genes.
2.1 Phospho-Smad2 protein level is increased upon inhibition of proteasome
activity
Upon TGF-ß ligand binding to the receptor complex, Smad2 is phosphorylated and
migrates to the nucleus, where it regulates the transcription of TGF-ß-response genes.
Subsequently, phospho-Smad2 is labelled with a multiubiquitin chain via the action of
Smurf2 ubiquitin ligase, and then is selectively targeted for proteasome-dependent
degradation. If this degradation is averted, the phospho-Smad2 remains in the nucleus
in an active state (reviewed by Massagué, 1999; Lo and Massagué, 1999; Wotton and
Massagué, 2001).
In Mv1Lu mink lung epithelial cells, treatment with TGF-ß rapidly elevated
phospho-Smad2 level at 1 h, and the induction persisted till at least 16 h, though the
total protein level declined (II, Fig. 1). Treatment of these cells with an inhibitor of
proteasome, MG132, which blocks the chymotryptic activity of the 26S proteasome,
gradually led to a rise in the phospho-Smad2 level (II, Fig. 1). A combination of TGF-
ß and MG132 raised the level of phospho-Smad2 over that of TGF-ß alone (II, Fig. 1).
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Immunofluorescence analysis indicated a clear accumulation of phospho-Smad2 in
the nucleus after TGF-ß and MG132 treatment (II, Fig. 3).
TGF-ß receptor and Smad7 are also degraded via the proteasome pathway (Kavask
et al., 2000). Their protein levels, however, were not examined in this study, since
Smad2 was phosphorylated and accumulated in the nucleus upon the treatment with
TGF-ß and MG132, which suggested that the upstream events of TGF-ß signaling
pathway functioned properly.
2.2 MG132 prevents TGF-ß-mediated downregulation of SnoN level
SnoN functions like a “switch” in TGF-ß signal transduction: it interacts directly
with Smad2/3-Smad4 complexes and represses their transactivation capabilities, thus
shutting off TGF-ß signaling (Akiyoshi et al., 1999; Sun et al., 1999; Leong et al.,
2001). In response to TGF-ß treatment, Smad2 and Smad3 recruit Smurf2 and APC
E3 ligases, respectively, to SnoN and target SnoN to the proteasome-dependent
degradation, thereby relieving SnoN-mediated repression and allowing TGF-ß signal
to go through (Bonni et al., 2001; Stroschein et al., 2001; Wan et al., 2001).
Meanwhile, TGF-ß is able to enhance SnoN expression transcriptionally, which
constitutes a negative feedback loop to limit TGF-ß signaling (Stroschein et al.,
1999).
To address the regulation of SnoN by TGF-ß and the proteasome system, we
treated Mv1Lu cells with TGF-ß and MG132 and analyzed the SnoN protein levels.
TGF-ß rapidly reduced the SnoN level, and the low levels were maintained at least
until 16 h, as shown both by immunoblotting and immunofluorescence (II, Fig. 2 and
3). Even though Stroschein et al. (1999) reported that in Hep3B cells a 2 h treatment
with TGF-ß induced SnoN protein due to an increase in SnoN mRNA (Stroschein et
al., 1999), we did not observe any elevation in SnoN by TGF-ß. Treatment of Mv1Lu
cells with MG132 caused an increase in SnoN level (II, Fig. 2), indicating that it
underwent proteolytic degradation also in the absence of TGF-ß. MG132 treatment
did not prevent the initial reduction in SnoN by TGF-ß, but increased SnoN protein
progressively and completely blocked TGF-ß-mediated reduction by 16 h (II, Fig. 2
and 3). Thus, TGF-ß reduced SnoN protein and this reduction was abolished by
MG132 but only after the prolonger incubation.
2.3 Inhibition of proteasome activity selectively alters expressions of TGF-ß-
response genes
In response to TGF-ß, Smad complexes accumulate in the nucleus, where they
either bind directly to DNA or associate with other transcription factors to regulate
transcription of a large number of genes. SnoN is capable of recruiting a transcription
co-repressor N-CoR/mSin3A to the Smad complexes, which in turn associates with
HDAC, promoting histone deacetylation and repressing TGF-ß-mediated
transcriptional activation. As treatment of Mv1Lu cells with MG132 led to the
accumulation of both phospho-Smad2 and SnoN in the nucleus, we addressed how
TGF-ß-responsive genes, including c-myc, p15, junB, and PAI-1, were regulated in
the presence of both an activator and an inhibitor.
Northern analysis showed that the induction of junB by TGF-ß was intact by 2 h in
the presence of MG132, and the induction was no longer detectable after 4 h
treatment, due to the nature of junB as an early response gene (II, Fig. 4). Reduction
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of c-myc by TGF-ß was observed only after 16 h treatment, and this effect was
completely abolished by MG132 (II, Fig. 4). p15 was induced by TGF-ß at 2 h, as
well as in the presence of MG132, but the induction was attenuated by MG132 at 4 h
and was completely blocked after 16 h (II, Fig. 4). Although the initial induction of
PAI-1 in the presence of MG132 was lower than that observed in cells treated with
TGF-ß alone (II, Fig. 4), the inductions were comparable at 4 h as well as at 16h. The
intact PAI-1 induction at the late timepoint excludes the possibility that the altered
regulations of c-myc and of p15 are due to the stress induced by MG132 treatment.
MG132 thus alters TGF-ß-mediated transcriptional regulation in a gene-specific
manner. It has a limited effect on the expression of TGF-ß-response genes early on,
but selectively inhibits the regulations of c-myc and p15 by TGF-ß at a late timepoint
(16 h). Regulation of TGF-ß target genes via the Smad-signaling pathway can utilize
either Smad2- or Smad3-dependent events or requires both Smads. Piek et al. (2001)
show, by using Smad2 or Smad3 null cells, that while TGF-ß induction of p15
requires both Smad2 and Smad3, the regulation of PAI-1 and of junB requires only
Smad3 (Piek et al., 2001). Accordingly, our observation that downregulation of the
proteasome allows TGF-ß induction of PAI-1, but not of p15, is suggestive that the
Smad3 pathway is intact, whereas the Smad2-dependent pathway is affected by
MG132. SnoN is able to associate with both Smad2 and Smad3 and inhibit their
activities. The potential selectivity of SnoN towards either Smad2 or Smad3 may arise
from differences in relative levels of the respective proteins or other factors
determining their interactions and thus the ability of SnoN to repress Smad-dependent
transcription. The blocking of TGF-ß signaling only towards specific target genes
suggests that proteasome activity is required selectively in the TGF-ß signal
transduction pathway.
3 Proteasome activity is required for TGF-ß-induced G1 cell cycle
arrest (III)
Proteasome activity is required for the cell to traverse through both the S- and
G2/M-phases of the cell cycle (Koepp et al., 1999). The proteasome takes care of the
degradation of certain cell cycle machinery proteins and determines their periodic
levels during the cell cycle (Thullberg, 2000). The proteasome system also controls
the degradation of several G1/S-phase regulators, including cyclin D, p27, and cyclin
E (for details see Review of the Literature section 3.3), which are also the targets of
the TGF-ß-mediated G1 cell cycle inhibition program. We therefore examined the
effect of the proteasome on TGF-ß-induced growth arrest, utilizing the proteasome
inhibitors MG132 and lactacystin.
3.1 Proteasome inhibitors abolish TGF-ß-mediated G1-phase arrest in mink lung
epithelial cells
Mv1Lu cells were treated with TGF-ß in the presence or absence of the proteasome
inhibitors MG132 and lactacystin. TGF-ß-induced G1-phase arrest was fully
overcome by the inhibitors, and cells entered the S-phase (III, Fig. 1). Furthermore,
treatment by MG132 caused an increase in the S-phase population (III, Fig.1),
indicating that the cells can enter the S-phase, but they cannot complete the S-phase in
the presence of MG132. This is consistent with a report that MG132 prevents the
firing of late replication origins and block cells in S-phase (Yamaguchi et al., 2000).
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To address how the proteasome inhibitor-treated cells eradicate TGF-ß growth
arrest, we analyzed the phosphorylation status of pRb. As shown in Fig. 3 (III), the
TGF-ß-mediated inhibition of pRb phosphorylation was attenuated following MG132
treatment, and almost all of the pRb protein remained in phosphorylated forms. This
suggests that the Cdks phosphorylating pRb are still active after TGF-ß treatment in
the presence of MG132. Following the treatment with both TGF-ß and MG132, a
small amount of pRb was, however, still maintained in the hypophosphorylated form
(Yamaguchi et al., 2000).
3.2 TGF-ß-reduced cyclin D-Cdk4/6 kinase activities are overcome by MG132
Subsequently, we examined the changes in cell cycle regulators affecting the G1/S-
phase transition in TGF-ß- and MG132-treated cells. As expected, cyclin D2 and p27
protein levels were increased by MG132 (III, Fig. 3). Interestingly, following
treatment of the cells with both TGF-ß and MG132, the reduction in Cdk4 and Cdk6
usually observed in TGF-ß-arrested cells (Reynisdottir et al., 1997; Tsubari et al.,
1999; I), was abolished (III, Fig. 3). Though treatment with TGF-ß destroyed cyclin
D2-Cdk4/6-p27 complexes in mink cells as described previously (Reynisdottir et al.,
1997), these complexes were maintained in the presence of MG132 (III, Fig. 4).
Furthermore, compared with the control sample, treatment with MG132 increased the
amount of cyclin D2-Cdk4/6-p27 complexes (III, Fig. 4), probably due to the
increased levels of cyclin D2 and p27 (III, Fig. 3), which are able to recruit more
Cdk4 and Cdk6 to form complexes. These complexes were maintained in cells treated
with both TGF-ß and MG132 (III, Fig. 4).
In line with the increased amount of cyclin-Cdk-p27 complexes in the presence of
MG132, we observed two- to three-fold enhanced cyclin D2-related kinase activity
toward pRb (III, Fig. 4), whereas in the TGF-ß-treated sample, the activity was
reduced by 60% (III, Fig. 4). Thus, MG132 maintains Cdk4/6 kinase activity in TGF-
ß-treated cells through increasing cyclin D and p27 protein levels and preventing the
downregulation of Cdk4/6 protein levels.
3.3 Cyclin E-Cdk2-associated kinase activity is abolished by MG132
TGF-ß induces relocalization of p27 to the cyclin E-Cdk2 complex and inhibits its
kinase activity (Reynisdottir et al., 1997; Stroschein et al., 2001). To test whether
function of the cyclin E-Cdk2 complex is affected by MG132, we analyzed the level
of the cyclin E-Cdk2 complex and its activity in TGF-ß- and MG132-treated cells.
Addition of TGF-ß led to the association of p27 with cyclin E-Cdk2 complex and
inhibited its kinase activity (III, Fig. 5). The cells treated with MG132 alone also
showed an increase in p27 in the cyclin E-Cdk2 complex (III, Fig. 5) which is
probably due to the accumulation of p27 protein after inhibition of its proteasome-
dependent degradation. The increase of p27 in cyclin E-Cdk2 complex led to
complete loss of cyclin E-associated activity and attenuated Cdk2-related kinase
activity (III, Fig. 5). The remaining activity in Cdk2 may come from other Cdk2-
associated complex for example, with cyclin A, which regulates the progression of S-
phase. Treatment with both TGF-ß and MG132 displayed a similar effect as that of
treatment with MG132 alone (III, Fig. 5). Thus, in contrast to the D-type cyclin-Cdk
complex, which is activated by MG132, the cyclin E-Cdk2 complex is suppressed
upon MG132 treatment. The loss of cyclin E-Cdk2 kinase activity may be an
explanation for the small amount of hypophosphorylated pRb observed in the cells
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treated with MG132 (Fig. 3). Since it is well accepted that full phosphorylation of
pRb requires both cyclin D and cyclin E activities, our finding that in the presence of
MG132, the majority of pRb is still phosphorylated without cyclin E activity is
surprising. Furthermore, our data indicated that MG132 is able to override TGF-ß-
mediated G1-phase arrest without cyclin E-associated activity. This suggests that the
activity of cyclin E may not be required for the escape of cells from TGF-ß-induced
cell cycle arrest, and it is also possible that a compensating factor for cyclin E-Cdk2
kinase exists, triggering the S-phase entry. Although cyclin E is also reported to be
degraded through proteasome (Clurman et al., 1996), we observe no increase in cyclin
E in the complex with Cdk2 (III, Fig. 5).
In summary, we observed that proteasome inhibitors overcome the TGF-ß-
mediated G1-phase block, indicating that TGF-ß-induced G1 cell cycle arrest requires
the activity of the proteasome. Proteasome inhibitors are one of the few factors that
can override the potent TGF-ß-mediated growth arrest of Mv1Lu cells. These include
factors directly targeting pRb, such as SV40 T antigen, overexpression of E2F, or
factors affecting the levels of Cdks, like HGF (Laiho et al., 1990; Ewen et al., 1993;
Schwarz et al., 1995; Taipale and Keski-Oja, 1996; Tsubari et al., 1999; Warner et
al., 1999). We have reported that HGF and overexpression of Cdk6 and Cdk4 block
TGF-ß-induced growth inhibition (Tsubari et al., 1999; I) and drive the reentry of
TGF-ß-arrested cells into the cycle (I). In contrast, the TGF-ß resistance mediated by
the proteasome inhibitor is observed only before cells are arrested by TGF-ß. HGF or
overexpression of Cdk4 and Cdk6 induce Cdk4/6 protein basal levels, thus increasing
their kinase activities. Proteasome inhibitors, however, protect Cdk4 and Cdk6 from
TGF-ß-induced reduction but cannot increase their protein levels and hence fail to
restore their activities in those cells which are already arrested by TGF-ß. This
indicates, from another angle, that downregulation of Cdk activities is crucial for
TGF-ß-induced G1-phase arrest and that the recovery of Cdk4/6 activity is efficient in
overriding this arrest.
In Studies II and III we examined the effects of the proteasome inhibitors on TGF-
ß signal transduction and TGF-ß-enforced cell cycle arrest. Treatment with the
proteasome inhibitor MG132 selectively blocked the induction of p15  at 16 h,
whereas the induction was unaffected at 2 h and was partially maintained at 4 h. Thus
the initial regulation of p15 by TGF-ß still occurred, indicating that the TGF-ß cell
cycle inhibition program through p15 could be initiated. Further on, treatment with
MG132 also increased cyclin D and p27 protein levles and prevented the reduction of
Cdk4 and Cdk6, hence allowing the active cyclin D complexes to form. Therefore,
proteasome inhibitor MG132 affects TGF-ß function at multiple steps and abolishes
TGF-ß-mediated G1-phase arrest.
4 SnoN is a novel prognostic marker in ER-positive breast carcinoma
(IV)
TGF-ß is a potent inhibitor of mammary epithelial cells and regulates mammary
development (Daniel et al., 1989; Barcellos-Hoff and Ewen, 2000). Although normal
human mammary epithelial cells are exquisitely sensitive to TGF-ß (Hosobuchi and
Stampfer, 1989), breast cancer cells require higher levels of TGF-ß to produce an
anti-mitogenic effect, and most cell lines show a complete loss of this response
(reviewed by Fynan and Reiss, 1993). However, in breast cancer, TGF-ß stimulates
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invasion (Welch et al., 1990; Oft et al., 1996) and bone metastasis in animal models
(Yin et al., 1999; reviewed by Dumont and Arteaga, 2000), suggesting that the growth
inhibitory function of TGF-ß is ignored, while other effects are maintained. In
contrast to other carcinomas, such as gastrointestinal cancers, lymphoma, lung cancer,
and ovarian cancer, which carry the deletions or inactive mutations of TGF-ß-
signaling components, breast cancers usually have intact TGF-ß signal transducers
(Yokota et al., 1997; Xie et al., 2002; reviewed by Kretzschmar, 2000). This indicates
the existence of other mechanism specifically affecting TGF-ß effects in breast
cancers.
SnoN is an inhibitor of TGF-ß signal transduction. It recruits transcriptional co-
repressors to Smad complexes and represses TGF-ß signaling (Akiyoshi et al., 1999;
Sun et al., 1999; Leong et al., 2001). To examine the possible role of SnoN in breast
tumorigenesis and progression, we examined the protein levels of SnoN in 1122
human primary breast cancer tissues included in the FinProg tissue microarray by
immunohistochemical staining. The association of SnoN expression with other
clinical and pathological features, as well as the prognostic value of SnoN were
analysed.
In this study, a polyclonal goat-anti human SnoN antibody was used in the
immunohistochemical staining, and the specificity of this antibody was tested by use
of a blocking peptide. In the statistical analysis, P  values less than 0.05 were
considered as statistical significant. All statistical tests were two-sided.
4.1 SnoN is expressed in cytoplasm and nucleus in normal and breast carcinomal
tissues
To understand how SnoN is expressed in normal human mammary tissue, we first
examined its expression in reduction mammoplasties. Although SnoN has been
reported to be a nuclear protein in culture cells (Shinagawa et al., 2000), the staining
in histologically normal sections of reduction mammoplasties showed both
cytoplasmic as well as nuclear SnoN at a moderate level. The cytoplasmic and nuclear
staining of SnoN appeared in the epithelial cells lining the mammary terminal ductal
unit, and the nuclear SnoN was present in the epithelial cells lining the larger
mammary ducts (IV, Fig. 1).
 Expression of SnoN was eveluated in 1 122 cases of breast cancers included in the
FinProg tissue microarray. As shown in Table 1 and Fig. 2 (IV), we found 21.0% of
the tumors with moderate to high (scored as 2-3, hence high) levels of cytoplasmic
SnoN, 19.3% with high levels of nuclear SnoN, and 49.5% with high levels of SnoN
in both cytoplasm and nucleus. Interestingly, the SnoN level was negative or low
(scored as 0-1, hence low) in 10.2% of the tumors in both cytoplasm and nucleus.
Thus the tumor tissues showed variation both in SnoN expression levels and in the
subcellular localizations.
Expression of SnoN was also examined in 20 other types of human tissues
including adrenal, thyroid, tonsil, lymph node, spleen, liver, pancreas, stomach, colon,
bladder, kidney, prostate, testis, lung, heart, brain, ovary, myometrium, muscle, and
parotid. Only thyroid, kidney, and pancreas showed positive staining of SnoN.
4.2 Expression pattern of SnoN is associated with certain types of breast cancer
To evaluate the significance of the expression pattern of SnoN in breast
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carcinomas, we analyzed the association of SnoN expression with other clinical and
pathological markers of breast cancer provided in the FinProg database. We found
that expression of SnoN was strongly associated with certain histological tumor types
and some prognostic markers (IV, Table 2). Nuclear SnoN expression was
significantly more frequent in lobular tumors, grade I and II tumors, estrogen receptor
(ER)-positive tumors, and tumors with low levels of p53, Ki-67, or Cox-2. On the
other hand, cytoplasmic expression of SnoN was significantly more frequent in ductal
tumors, grade III tumors, ER- and progesterone receptor (PgR)-negative tumors,
ERBB2-amplification-tumors, and tumors with high levels of p53, Ki-67, and Cox-2.
On the other hand, SnoN expression was not significantly associated with
patients´age (year 50 was used as the cut-off), or with tumor size (2 cm as the cut-off),
and did not associated with lympho node metastases. There was no significant
association between cytoplasmic and nuclear expression of SnoN.
4.3 SnoN is a prognostic marker in breast carcinoma
Analysis of distant disease-free survival (DDFS) of patients with various
expression patterns of SnoN suggested that reduced expression of SnoN may be a
prognostic marker (IV, Table 3, Fig. 3).
In all tumors, the low level of SnoN in both nucleus and cytoplasm indicated a
statistically significant better survival as compared with high levels of SnoN either in
the nucleus, or cytoplasm, or both, whereas the low level only in the nucleus or only
in the cytoplasm did not improve the outcome (IV, Table 3, Fig. 3).
The same results have been observed in several subgroups of the tumors. Low
expression of SnoN in both nucleus and cytoplasm indicated a better prognosis in
patients with tumors positive for ER or PgR, tumors of the ductal type, tumors of
grades I-II, or tumors with a low level of Cox-2 (IV, Table 3).
As the analysis strongly suggested that a low level of SnoN in both cytoplasm and
nucleus improved the survival of ER-positive patients (P = 0.0027), we analyzed the
prognostic value of SnoN in ER+ patients in detail. A low level of cytoplasmic SnoN
also associated with longer DDFS as compared with high cytoplasmic SnoN (P =
0.0076), while a low level of nuclear SnoN did not, as compared with high nuclear
SnoN (P = 0.1965). Analysis of DDFS according to different combinations of SnoN
expression levels and subcellular localizations indicated that even in the presence of
reduced cytoplasmic SnoN, its combination with high nuclear SnoN associated with
shorter DDFS, as compared with low SnoN in both cytoplasm and nucleus (IV, Fig.
3). This suggests that reductions in both cytoplasmic and nuclear SnoN are important
for better outcome.
In this study we presented the first in vivo analysis of the expression of SnoN in
human breast carcinoma tissues. Cytoplasmic SnoN was more frequently found in the
ductal tumors and was associated with adverse prognostic features, whereas nuclear
SnoN was associated with lobular tumors and favorable features. Nuclear SnoN has
been suggested to function in the regulation of transcription, while there is little
evidence about the function of cytoplasmic SnoN. Reed et al. (2001) reported that the
subcellular localization of Ski, an analogue of SnoN, changed in vivo from the
nucleus in melanoma in situ, to the nucleus and cytoplasm in primary invasive and
metastatic melanomas (Reed et al., 2001). Furthermore, their in vitro study suggested
that the Ski/Smad association in cytoplasm may prevent the nuclear localization of the
Smads in response to TGF-ß, implying another pathway by which Ski/SnoN blocks
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TGF-ß signaling (Reed et al., 2001). Accordingly, cytoplasmic SnoN observed in the
breast tissues may block the entry of Smad complexes into the nucleus, and the
nuclear SnoN may interfere directly with the Smad complexes and inhibits their
activities in the regulation of transcriptions.
We observed that a low level of SnoN was strongly associated with better
prognosis in ER-positive patients. There are several observations suggesting crosstalk
between TGF-ß signaling and estrogen signaling. Estrogen induces TGF-ß mRNA and
protein levels (Knabbe et al., 1987), and in breast cancer cells, tamoxifen increases
TGF-ß expression and secretion (Chen et al., 1996; Koli et al., 1997; Malet et al.,
2001). The expression of Ski is upregulated in response to estrogen signaling in
epithelial cells of the uterus, rasing the possibility that in breast tissue Ski and SnoN
may be involved in the interactions between estrogen and TGF-ß (Yamanouchi et al.,
1999). Our finding that reduction in SnoN protein level contributes to a better
prognosis in ER+ patients gives another indication that TGF-ß and estrogen pathways
may crosstalk.
A low level of SnoN in both cytoplasm and nucleus was observed in 10% of all the
patients and was significantly related to better prognosis. This suggests that those
tumors with a lower level of SnoN may respond to TGF-ß-mediated growth
regulation, and thus predict a better outcome. SnoN protein level oscillates during the
cell cycle (Pearson-White and Crittenden, 1997), and also undergoes regulation by
TGF-ß via the proteasome-mediated degradation (Wan et al., 2001; Bonni et al.,
2001). In Study II we reported that downregulation of proteasomal activity altered
TGF-ß signaling, probably through an increased SnoN, indicating that cellular SnoN
level was important for TGF-ß function. In future, it will be important to determine
how the protein level as well as the subcellular localization of SnoN are regulated
during breast tumorigenesis.
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CONCLUDING REMARKS
The present study is focused on the understanding of molecular mechanisms of
TGF-ß-induced G1 cell cycle arrest and its disruption in tumorigenesis both at the
signal transduction level and at the downstream cell cycle machinery level. The major
conclusions are:
I. Ectopic expression of Cdk6 circumvents TGF-ß-mediated growth inhibition. The
main effect of the ectopic expression of Cdk6 is to sequester TGF-ß-induced p15
and to maintain p27 in the cyclin D complex, hence preventing TGF-ß-induced
shift of p27 to the cyclin E-Cdk2 complex. This leads to the presence of the active
cyclin D complex and the partially active cyclin E complex, which in turn prevent
TGF-ß from fully inhibiting the cell cycle. However, the dominant negative Cdk6
protein is unable to overcome the anti-mitogenic effect of TGF-ß, suggesting that
not only an abundance of Cdk6 protein but also its intact kinase activity are
required for circumventing TGF-ß-induced growth inhibition.
      II. Inhibition of proteasome activity leads to accumulations of both positive and
negative transducers of TGF-ß signaling, phospho-Smad2 and SnoN. The
regulations of TGF-ß-responsive genes are affected by the proteasome inhibitor
differently. Whereas the regulation of c-myc and p15 are lost, PAI-1 induction is
still maintained. These results suggest that proteasomal activity modulates TGF-ß
signaling in a gene-specific manner.
III. Proteasomal inhibitors overcome TGF-ß-mediated growth arrest. Abolition of
proteasomal function enhances the activity of cyclin D-associated complexes by
increasing the levels of cyclin D and p27 and preventing the reduction in Cdk4
and Cdk6. Cyclin E-associated activity is suppressed due to the increase in p27,
although pRb is still phosphorylated, suggests that pRb can be phosphorylated
also by kinases independent on cyclin E. This finding indicates that TGF-ß-
induced G1 cell cycle arrest requires the activity of the proteasome pathway.
IV. SnoN, an inhibitor of TGF-ß signaling, is found to be expressed in breast cancers
at varying levels and subcellular localizations. Cytoplasmic SnoN is more
frequent in ductal tumors and is related to adverse prognostic markers. Nuclear
SnoN is mainly present in lobular tumors and correlated with favorable prognostic
markers. Furthermore, reduced SnoN in both cytoplasm and nucleus is
significantly related to better prognosis. Immunohistochemical staining of SnoN
may therefore serve as a prognostic marker to predict the outcome in breast cancer
patient.
Our findings imply that the cell cycle block enforced by TGF-ß requires an intact
TGF-ß signal transduction pathway and the proper functions of the cell cycle
machinery components. Alterations in these multiple steps will attenuate the effect of
TGF-ß and favor uncontrolled growth. Further studies on the mechanisms of TGF-ß
signal transduction and TGF-ß-induced cell cycle inhibition in both normal and
cancer tissues will give more insights into the understanding of tumorigenesis.
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